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palavras-chave 
 
Infeção do trato urinário, cistite, tratamento, resistência 
resumo 
 
 
A infeção do trato urinário é a segunda infeção mais comum na comunidade e 
a mais comum no contexto hospitalar a nível mundial. As crianças, grávidas, 
idosos, diabéticos, pacientes com deformidades urológicas, cateterizados e 
imunodeficientes são considerados população de risco e por isso são mais 
propensos a desenvolver infeção do trato urinário. 
As amostras estudadas foram colhidas em regime de ambulatório no 
laboratório de análises clínicas, Centro Médico da Praça Lda, no município de 
São João da Madeira, distrito de Aveiro (Portugal), durante o período de 
estudo entre junho de 2011 a junho de 2014. 
E. coli (64%) foi a bactéria patogénica mais frequente, seguida da Klebsiella 
spp (12%), de Enterococcus spp (7%) e P. mirabilis (6%). 
Das 4270 urinas analisadas, 3561 (83%) foram colhidas em mulheres e 
apenas 709 (17%) em homens, num intervalo de idade entre 0 e os 104 anos. 
Desta amostra 1537 (37%) eram multirresistentes, entre elas 1099 foram 
colhidas de mulheres e 437 de homens. As bactérias patogénicas 
multirresistentes foram em média resistentes a 6 antibióticos e a 5 classes de 
antibióticos. Na generalidade os homens foram mais resistentes que as 
mulheres. 
Os resultados do estudo mostraram que dos antibióticos de primeira linha de 
tratamento apenas a nitrofurantoína é apropriado no tratamento empírico para 
ambos os sexos. Dos antibióticos sugeridos pela EAU como segunda linha de 
tratamento, a Amoxicilina - ácido clavulânico e o sulfametoxazole - trimetoprim 
pode ser considerado apenas para tratar mulheres, por fim, a ampicilina não é 
adequada para aos pacientes deste estudo. Deste modo, é sugerido como 
alternativa os antibióticos imipenem e gentamicina para o tratamento empírico 
de ambos os sexos. 
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abstract 
 
The urinary tract infection is the second most common infection in community 
and the most common nosocomial infection worldwide. Specific subpopulations 
are more likely to have UTI, such as, infants, pregnant women, elderly, 
diabetics, patients with urologic abnormalities, patients with catheters and 
immunodeficients.  
All the samples were collected at Centro Médico da Praça Lda on ambulatory 
system, located in São João da Madeira municipality, District of Aveiro north 
(Portugal) from June 2011 to June 2014.  
From 4270 analysed urine samples, 3561 (83%) were collected from women 
and only 709 (17%) were collected from men, in a range age from 0 to 104 
years old. E. coli was (64%) the most frequent uropathogen, followed by 
Klebsiella spp (12%), Enterococcus spp (7%) and P. mirabilis (6%). 
From all samples, 1537 (37%) were multidrug resistant (MDR), 1099 were from 
women and 437 from men. The MDR uropathogens were resistant on average 
to a 6 antimicrobials and to a 5 antimicrobial classes of drugs. In general, men 
were more resistant to antimicrobials than women. 
According the results of this study, among the first line drugs recommended by 
EUA for empirical treatment of UTI the antimicrobials only nitrofurantoin is 
suitable for both sexes and ciprofloxacin may be only considered to treat 
women. From EAU recommended second line therapy, ampicillin is not 
appropriated to empirical treatment for both sexes, amoxicillin-clavulanic acid 
and trimethoprim-sulfamethoxazole should not be considered for men UTI 
empirical treatment, due the local high incidence of resistance. Thus, it is 
suggested imipenem and gentamicin as alternatives to treat both sexes. 
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CHAPTER I - INTRODUCTION 
1. HISTORY 
Urinary tract infection (UTI) is the second most common infection in 
community and the most common nosocomial infection worldwide (Girard, et al., 
2002; Roriz-Filho, et al., 2010; Al-Badr, et al., 2013; Ott, et al., 2013; Sujatha, et al., 
2014). Due to its prevalence, it has high impact on ambulatory healthcare costs, 
caused by many visits to a physician, diagnostic tests and prescriptions (Kapoor, et al., 
2012; Al-Badr, et al., 2013). 
TABLE 1 Classification of urinary tract infection episodes in six categories (Al-
Badr, et al., 2013). 
Classification Description 
Uncomplicated infection The urinary tract is normal, both 
structurally and physiologically, and there is no 
associated disorder that impairs the host defence 
mechanisms 
Complicated infection When infection occurs within an 
abnormal urinary tract, such as when there is 
ureteric obstruction, renal calculi, or 
vesicoureteral reflux. 
isolated infection The first episode of UTI, or the episodes 
are 6 months apart. Isolated infections affect 25–
40% of young females. 
unresolved infection When therapy fails because of bacterial 
resistance or due to infection by two different 
bacteria with equally limited susceptibilities. 
reinfection Occurs when there has been no growth 
after a treated infection, but then the same 
organism regrows two weeks after therapy, or 
when a different microorganism grows during 
any period of time. 
relapse When the same microorganism causes a 
UTI within two weeks of therapy; however, it is 
usually difficult to distinguish a reinfection from a 
relapse. 
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The episode of UTI is classified as lower and upper urinary tract infection 
according to where it occurs: urethritis in urethra, cystitis in bladder, bacteriuria in 
urine and pyelonephritis in kidney and ureters (Barber, et al., 2013). UTI may involve 
either lower and upper urinary tracts, or most often only the lower urinary tract 
(Rowe, et al., 2013). It is denominated as uncomplicated urinary tract infection (U-UTI) 
when it occurs in a young women non-pregnant with a normal genitourinary tract. 
Whereas the complicated urinary tract infection (C-UTI) occurs in a genitourinary tract 
with structural or functional abnormalities, including catheterized patients (Roriz-Filho, 
et al., 2010).  
Typical UTI symptoms are pain, fever, urgency and frequency of micturition, 
dysuria (painful micturition), suprapubic cramping pain and sense of weight, turbid or 
cloudy urines, sometimes with an unpleasant smell, nocturia and haematuria. Usually 
the symptoms of lower urinary tract infection are slight, or absent in case of 
asymptomatic bacteriuria (ASB). In women, ASB is defined as the presence of two 
consecutive urine specimens positive for the same bacterial strain in quantities equal 
or superior to 105 CFU/ mL (Rowe, et al., 2013). In men, the microbiologic criteria for 
diagnosis of ASB is not as well rendered valid, some authors define as a single voided 
specimen with one bacterial isolate in quantities equal or superior to 104 CFU/mL 
(Grabe, et al., 2014).  
Ascending infection causing pyelonephritis (upper urinary tract infection), 
causes back pain and costovertebral angle tenderness and can also be accompanied 
with symptoms of malaise, fever, nausea and vomiting in severe infections. If bacteria 
enters the blood stream it may lead to severe complications, including septicaemia, 
shock and, rarely, death (Kapoor, et al., 2012; Al-Badr, et al., 2013) 
The UTI prevalence is significantly higher in women than men, likely as a result 
of anatomic differences, due the proximity of urethra to anus which provides the self-
colonization by gastrointestinal pathogens (Al-Badr, et al., 2013). Also, the shorter 
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urethra in women can facilitate bacterial transit from the urethral opening to the 
bladder (Figure 1). Ureteral massage and trauma during sexual activity also enables the 
pathogens ascension to bladder (Roriz-Filho, et al., 2010; Kapoor, et al., 2012; Barber, 
et al., 2013). Urinary tract infections in men, elderly people, pregnant women, or 
patients who have an indwelling catheter or an anatomic or functional abnormality are 
considered complicated urinary tract infections (C-UTI) (Jancel, et al., 2002; Nicolle, et 
al., 2005). 
 
FIGURE 1 Urinary tract systems and their anatomic singular characteristics. 
Adapted from: http://healthcare.utah.edu/healthlibrary/related/doc, retrieved 9 24, 
2014. 
Recurrent urinary tract infection (R-UTI) is defined by three positive urine 
cultures during a 12-month period, or two infections during a 6 months period caused 
by the same pathogen (Graziottin, 2014). The incidence of R-UTI increases with age, 
sexual activity (post-coital cystitis) and medical illnesses complications such as diabetes 
mellitus (Al-Badr, et al., 2013).  
Uncomplicated R-UTI associated with the uropathogenic Escherichia coli (UPEC) 
are common among healthy, sexual active and reproductive age women. 
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Uncomplicated R-UTI after intercourse is responsible for 60% of recurrent cystitis 
(Graziottin, 2014). Other factors contributing to R-UTI persistence are urinary tract 
obstruction, incomplete voiding, aberrant structural anatomy and accumulation of 
bacteria in unreachable locations for antibiotics, such as kidney stones (Al-Badr, et al., 
2013; Barber, et al., 2013). 
2. FACTORS OF SUSCEPTIBILITY 
Specific subpopulations with increased risk of UTI include infants, elderly, 
pregnant women, patients with urologic abnormalities, patients with catheters, 
diabetes and other immunodeficiency diseases (Foxman, 2002). 
2.1. INFANTS 
UTI is a non-reported cause of childhood morbidity because it is not included in 
the current Integrated Management of Childhood Illness (IMCI), however it has been 
estimated that 1% of boys and 3% of girls are diagnosed with UTI (WHO, 2005). 
Contrary, in the first year of life UTI is more prevalent in boys with rates of 2.7% 
compared with 0.7% in girls, also uncircumcised boys have increased risk for 
developing UTI (Chang, et al., 2006; Edlin, et al., 2014). 
Surveys have demonstrated that ASB in children of all ages, however it is 
accepted that ASB does not present a risk to a child.  The detection of for ASB in child 
is not indicative of illness (WHO, 2005). Treatment of ASB can promote the growth of 
resistant organisms by selective pressure. Studies using components of human breast-
milk have suggested that breastfeeding may provide some protection against UTI in 
childhood (Parida, et al., 2013; Edlin, et al., 2014). 
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2.2. ADULTS 
The gender vulnerability is clear for UTI, women have 50 times more chances of 
acquiring UTI than men over all age groups (Graziottin, 2014). Most U-UTI occurs in 
women without any anatomic or functional abnormality and the seriousness varies 
from mild to severe. It is estimated that 50-60% of all women after puberty experience 
at least one UTI episode during their lifetime and in 8% of UTI episodes the pathogens 
may stay silent (Kapoor, et al., 2012; Al-Badr, et al., 2013; Barber, et al., 2013; Rowe, et 
al., 2013). 
The UTI rates normally increase with the beginning of sexual activity in young 
patients, the post-coital symptoms in women last till 6 days on average (Graziottin, 
2014). The major cause of U-UTI post-coital is due to the ascension of vaginal bacteria 
to the urinary tract (Rowe, et al., 2013). Also post-menopausal women have higher 
rates of UTI due to pelvic prolapse, lack of estrogen, loss of lactobacilli in the vaginal 
flora (Graziottin, 2014). Additional risk factors include comorbidity associations that 
increase UTI susceptibility, however the majority of UTI occurs in healthy women (Al-
Badr, et al., 2013; Barber, Norton, et al., 2013). 
The large gender difference in the UTI prevalence is caused by many factors 
including: the greater distance between urethra and anus the usual source of 
uropathogens; the drier environment surrounding the male urethra; the greater length 
of the male urethra; and the antibacterial activity of the prostatic fluid. The UTI in a 
healthy adult men between the ages of 15 and 50 years old is very uncommon, 
however, it is more common the UTI sepsis evolution in men than in women. The exact 
reasons for UTI infections in healthy men are not clear, however some sex-related 
behaviours, such as, unprotected intercourse with an infected partner, unprotected 
anal intercourse and even the lack of circumcision seem to be associated (Nicolle, et 
al., 2005; Roriz-Filho, et al., 2010; Grabe, 2008).  
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Usually, UTI in men are generally viewed as complicated because most of UTI 
episodes occur in new-born, infant or elderly and they are related to urological 
abnormalities, bladder outlet obstruction, instrumentation of genitourinary or several 
other comorbidities, such as, diabetes and HIV (Nicolle, et al., 2005; Roriz-Filho, et al., 
2010; SIGN, 2012). 
Among men the UTI incidence increases after the age of 50 and it is associated 
with the prostatic disease and urinary catheterization (Nicolle, et al., 2005; Roriz-Filho, 
et al., 2010). Conditions like prostatitis, chlamydial infection and epididymitis should 
be considered in the differential diagnosis of men with acute dysuria (SIGN, 2012). 
In 90% of men the appearance of febrile UTI is associated to prostatitis, thus 
the urological evaluation should be carried out routinely in men whenever a 
complicating factor is suspected. Between 52% and 90% of men with a UTI have been 
reported to have prostatic involvement in the infection, which can result in prostatic 
abscesses or prostatitis (Grabe, et al., 2008). 
2.3. PREGNANCY 
Pregnant women in particular are vulnerable to UTI because pregnancy itself is 
an immunocompromised state (Kapoor, et al., 2012; Sujatha, et al., 2014). Pregnancy-
UTI incidence elevates up to 20% and frequently causes of premature delivery. It also 
increases the risk between 25 to 40% chance of ascending to upper urinary tract 
infection, hypertensive disease, anaemia, postpartum complications and foetal 
mortality (Foxman, 2002; Kapoor, et al., 2012; Sujatha, et al., 2014) 
Anatomical factors like the pressure of the enlarged uterus on the bladder, the 
physiological hormonal relaxant effect of progesterone on the smooth muscle of the 
urinary tract, the vesicoureteral reflux, may predispose to recurrent UTI (Figure 2) 
(Kapoor, et al., 2012). 
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FIGURE 2 Bladder compression during pregnancy. Adapted from: 
http://my.clevelandclinic.org/health/diseases_conditions/hic_Am_I_Pregnant/hic_Cop
ing_with_the_Physical_Changes_and_Discomforts_of_Pregnancy/hic-pregnancy-
childbirth-bladder-control, retrieved 9 24, 2014. 
It has been estimated that between 2% to 10% of women in developed 
countries will experience ASB or UTI in pregnancy. Unlike infants, the detection and 
treatment of ASB in pregnancy in several developed countries has resulted in birth 
outcomes improvement. Therefore, the ASB detection was recommended by the 
World Health Organization (WHO) antenatal care package to reduce prematurity, low 
birth weight, the neonatal morbidity and mortality (Gilbert, et al., 2013). 
2.4. ELDERLY 
ASB and UTI are the second most common infections in people over the age of 
65 years. In elderly group, particularly those living in long-term care facilities, are less 
likely to present genitourinary symptoms. In both men and women, the incidence of 
UTI increases substantially in elderly (Rowe, et al., 2013). Between 25% to 50% of 
elderly women and 15% to 40% of elderly men in long-term care facilities usually 
develop ASB and the majority of these elderly people have chronic neurologic illnesses 
(Nicolle, et al., 2005). In younger women, the estimated prevalence of ASB is 1–5%, 
increasing to an estimated 6–16% in women over 65 years of age.  
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The treatment for ASB is only recommended in elderly prior to transurethral 
resection of the prostate or any urologic procedures for which mucosal bleeding is 
anticipated. The differentiation of UTI from ASB must be looked at very carefully, 
because misclassification may occurs (Rowe, et al., 2013). 
Age-associated changes in immune function, exposure to nosocomial 
pathogens in case of institutionalized patients and the increasing number of 
comorbidities put the elderly at an increased risk for developing infection. Medical 
comorbidities, such as stroke and dementia, may predispose individuals to bowel and 
bladder incontinence, which have been associated with symptomatic UTI and 
persistent ASB (Rowe, et al., 2013). 
In older women, some studies suggest an association with menopause, due to 
the loss of estrogens and the worsening of constipation with age (Graziottin, 2014). In 
older men, prostatic hypertrophy causing obstruction to the normal flow of urine leads 
to high post void residual and it has been postulated to be a risk factor for UTI in old-
aged (Rowe, et al., 2013).  
2.5. CATHETER-ASSOCIATED UTI 
The catheter-associated UTI (CA-UTI) is a very common nosocomial infection 
and indwelling urethral catheter is a procedure exceedingly used in health care 
facilities, with 17.5% of patients in 66 European hospitals having a catheter (Nicolle, 
2014). Indwelling urethral catheter is generally considered to be short term if it is in 
situ for less than 30 days and chronic or long term when it is in situ for 30 days or 
more, in case of institutionalized adults (Nicolle, 2014).  
Catheterization is also a major cause of hospital-acquired UTI, which may be 
associated with enhanced nosocomial mortality rates (Parida, et al., 2013). The risk 
increases between 3% to 10% per day of catheterization, and at the 30th day of 
catheterization the infection rates are about 100%, which is an additional cost per 
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admission (Meddings, et al., 2014) (Parida, et al., 2013; Nicolle, 2014). For indwelling 
urethral catheter patients, ASB is defined as a positive urinary culture for one bacterial 
isolate in quantities ≥102 CFU/mL, in the absence of symptoms (Rowe, et al., 2013). 
Prevention of CA-UTI has recently become an important goal of health-care 
infection prevention programs. These programs criteria include aseptic insertion of 
urinary catheters, minimizing the use and duration of catheters, which has led to a 
decrease in the incidence of CA-UTI. In adults who require catheterization, the use of 
antimicrobial-coated catheters may delay bacterial colonization and thus decreases 
the incidence of CA-UTI (Rowe, et al., 2013; Nicolle, 2014) 
Potential risk factors resulting from prolonged catheterization and catheter 
insertion outside a protected environment, also put the patient at an increased risk 
(Parida, et al., 2013).  A recent study about cleaning the urinary catheter prior to the 
catheterization showed significant evidences that the use of water or saline solution 
reduces rates of UTI and suggests the realization and implementation of a new 
guideline to prevent CA-UTI. The aseptic insertion and maintenance of urinary catheter 
and system and its correct removal are relevant from the point of view of prevention 
and control of UTI (Figure 3). Also guidelines and previous studies indicate that urinary 
meatus should be cleaned with water or saline solution (Cunha, et al., 2013). Alternate 
voiding management strategies such as intermittent catheterization or/and, external 
condom catheters for men, should be used when possible (Nicolle, 2014). 
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FIGURE 3 The four stages of the urinary catheter lifecycle to decrease catheter 
use and CA-UTI. Adapted from (Meddings, et al., 2014). 
 
2.6. DIABETES-ASSOCIATED UTI 
Patients with Diabetes mellitus (DM) have a higher risk of ASB, R-UTI and 
pyelonephritis (Al-Badr, et al., 2013). DM is a progressive disease that is characterized 
by a state of chronic hyperglycaemia. Findings suggest that UTI are more commonly 
experienced by those with DM compared to those without DM. The exact mechanism 
is unknown, but several possibilities have been proposed to explain the association 
between these two diseases. The presence of higher glucose concentrations in the 
urine might promote UTI development by amplifying bacterial reproduction and 
creating a favourable environment for infections (Fu, et al., 2014). Women are more 
prone to ASB than men with diabetes, but in both sexes the progression to clinical 
pyelonephritis is more probable than in normal individuals. Women with type 1 
diabetes are particularly at risk if they have had diabetes for a long time or have 
developed complications, particularly peripheral neuropathy and proteinuria. The risk 
factors for developing ASB differ between type 1 and type 2 diabetes, usually the 
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patients with type 2 diabetes were old age, proteinuria, a low body mass index and a 
past history of R-UTI (Grabe, et al., 2014). 
Diabetes-associated UTI (DA-UTI) increases the risk of acute pyelonephritis by 
Enterobacteriaceae that usually infects the lower tract, also Klebsiella infection is 
particularly common (25% compared with 12% in non-diabetics). Other patient-related 
factors such as age, metabolic control and duration of diabetes have also been 
suggested as increasing the risk of infection among those with diabetes (Fu, et al., 
2014). 
3. DIAGNOSIS 
Urine contains an enormous amount of information, despite being a waste 
product. Urine bladder culture and microscopic urine sediment analysis have been the 
gold standards to urinalysis. Well-standardized procedures are the basis of an effective 
diagnostic strategy for urinalysis (Delanghe, et al., 2014; Sujatha, et al., 2014). 
The laboratory is responsible for giving the correct information to the patient 
about the best sampling procedures, including biological collection, conservation, 
storage and specimen transport to the laboratory. Since the patients themselves often 
collect the urine specimen, a flawless pre-analytical urinalysis depends on well-
standardized procedures. Therefore, for being a very susceptible procedure, the 
requirements of urinalysis have gained importance and have become stricter 
(Delanghe, et al., 2014).  
3.1. SPECIMEN COLLECTION 
To avoid contamination with urogenital flora the collection of urine specimen 
should be achieved by cleaning the hands and washing the glans penis of men or the 
introitus of women (Demilie, et al., 2014). Due to the influence on the viability of 
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bacteria, the use of soap or antiseptics is not recommended. Clean-catch urine or 
midstream portions of first morning urine samples (not less than 4 hours storage in the 
bladder) should be collected to a sterile urine container in order to avoid 
contaminations. The volume should be between 15 ml and 20 ml in a sterile urine 
container provided by the laboratory or purchased in a pharmacy. Samples are 
transported in the primary containers and stored at 4°C until be processed, the lack of 
temperature control can lower the quality of urinary test results (European 
Confederation of Laboratory Medicine, 2000).  
Catheter-urine specimens for culture should be collected directly from the 
catheter or tubing, to maintain a closed drainage system. These may be collected 
either through the catheter collection port or through puncture of the tubing with a 
needle (Nicolle, 2014). 
In case of an incorrect specimen collection, the urine collection must be 
repeated. The conservation procedure is also a limiting factor for the over-all 
diagnostic accuracy, urine samples must be refrigerated so that a precise urinalysis can 
be processed within 24 hours (Delanghe, et al., 2014). A proper pre-analytical 
procedure is crucial to urinalysis. 
3.2. URINALISYS 
The experimental and analytical procedures follow the norms from the Clinical 
and Laboratory Standards Institute (CLSI, 2010).  
On arrival at the laboratory the samples are triaged and 10-15 mL from the 
original sample are transferred into one examination tube to the dipstick analysis in 
order to detect nitrite (indicative of microbial activity) and leucocyte esterase 
(indicative of pyuria). 
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Microscopic analysis of the urine sediment is performed after centrifugation at 
1500 rpm for 5 minutes, haematuria (erythrocytes) and pyuria (neutrophils) are 
searched, if superior to 10 cells per high power field may be diagnosed with 
bacteriuria. This optional analysis contributes to the diagnosis of UTI and it may 
suggest abnormalities and vulnerabilities that could lead to a complicated UTI (Barber, 
et al., 2013). 
Then, gram stain is used to differentiate bacterial species into gram-positive 
and gram-negative. Dipstick test, that detects nitrite and leucocyte esterase, is also 
used to diagnose UTI (Gieteling, et al., 2014). 
The urine culture procedure is performed by vertical immersion with a 
disposable plastic loop of 1 µl into the original sterile container and spread horizontally 
on the surface of the chromID™ CPS® plates (bioMérieux SA, 2013). Then, plates are 
incubated at 37 °C in aerobic atmosphere for 18 hours. After incubation, all the 
negative cultures, if growth is inferior to 103 CFU/mL, are excluded. 
ChromID™ CPS® is an isolation and identification medium that is used for 
urinary samples and enables the microbial count of the sample through the 
standardized seeding method. The colonies of E.coli are pink and red; Enterococcus are 
turquoise colonies; Klebsiella, Enterobacter, Serratia and Citrobacter are brown-
greenish colonies; Proteus, Providencia and Morganella are dark brown colonies 
expressing desaminase.  
The microbial criteria in urine culture is defined as a positive result to UTI, If  
growth is equal or superior to 105 CFU/mL in mid-stream sample of urine (MSU), with a 
maximum of 2 isolated microbial species. It is considered contamination if it has been 
observed 3 or more specimens in the culture, or if growth is equal or inferior to 103 
CFU/mL (Girard, et al., 2002; Roriz-Filho, et al., 2010). ASB is defined by the presence 
of bacteria in urine culture, if growth is inferior to 105 CFU/mL in MSU, without clinical 
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symptoms of infection and should not be treated in young non-pregnant women 
(Roriz-Filho, et al., 2010). To the subpopulations with increased risk of UTI and 
symptomatic should be considered positive culture, if growth is equal or superior to 
104 UFC/mL, such as, catheter samples, pregnant women, children and elderly. For 
suprapubic aspirated urine should be considered positive culture, if growth is equal or 
superior to 102 UFC/mL (Kapoor, et al., 2012).  
3.3. VITEK 2 DIAGNOSIS TOOL 
VITEK 2 system (bioMérieux) is an accurate and reproducible diagnostic tool 
that allows the determination of the exact etiology of patient’s infectious. With great 
automation, safety and minimal manual operations provides microbial identification in 
vitro on short time compared with conventional methods (Khardori, 2014) 
Nowadays Vitek 2 system is directed to clinical laboratories professionals, but it 
was originated with the National Aeronautics and Space Administration (NASA) space 
program to identify infections in astronauts (bioMérieux SA, 2009). The VITEK 2 system 
cards are the size and shape of a playing card and contain 64 microwells (Figure 4). 
Each well contains identification substrates or known antimicrobials in different 
concentrations in association with mass spectrometry and bioinformatics make the 
identification possible (bioMérieux SA, 2014 b; Khardori, 2014). 
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FIGURE 4 VITEK® 2 identification and antimicrobial susceptibility test cards. 
Adapted from: http://www.biomerieux-diagnostics.com/vitek-2-identification-cards, 
retrieved 10 17, 2014. 
3.3.1. VITEK 2 IDENTIFICATION 
For bacteria identification, the isolate is collected from a pure culture and 
inoculated in a saline suspension, with a density between 0.5-0.65 in McFarland scale. 
According to the colonies characteristics (colour, form, size and smell), it is chosen the 
VITEK® 2 GN ID Card to identify lactose fermenting and lactose non-fermenting gram-
negative bacilli, or VITEK® 2 GP ID Card to Identify gram-positive bacteria (Funke, et al., 
2004; bioMérieux SA, 2014 b). 
3.3.2. VITEK 2 ANTIMICROBIAL SUSCEPTIBILITY TEST (AST) 
In addition to VITEK® 2 ID Cards, it is performed  the VITEK® 2 AST Card 3 mL 
saline suspension, which is prepared from the VITEK® 2 ID Card suspension based on 
established concentrations. From gram-negative it should be taken 145 µl of the 
VITEK® 2 ID Card suspension, and from gram-positive it should be taken 280 µl of the 
VITEK® 2 ID Card suspension. After the preparation of both suspensions, VITEK® 2 ID 
Card and VITEK® 2 AST Card are introduced into the respective saline suspensions and 
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incubated at 36°C in the VITEK® 2 incubator, the results are available within 10 hours 
(bioMérieux SA, 2014 a). 
The antimicrobial susceptibility testing (AST) results are validated by the 
Advanced Expert System (AES) program, and follow the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) program. The determination of the 
phenotypic AST depends on minimal inhibitory concentration (MIC) breakpoints. The 
breakpoints allow the bacteria grouping into the categories: susceptible, intermediate, 
and resistance. Meanwhile it is also performed the ESBL-confirmation tests 
(bioMérieux SA, 2014 a; Stokkou, et al., 2014). 
The VITEK® 2 AST Cards most used in Portugal urinalysis are: VITEK® 2 AST-
GN26 (Portuguese card of urines), VITEK® 2 AST-GN86 VITEK® 2 AST-N113 for gram 
negative bacteria with resistance to majority of the antibiotics from the VITEK® 2 AST-
GN26 (Table 2); VITEK® 2 AST-P586 for gram positive Enterococcus and Streptococcus 
and VITEK® 2 AST P619 for Gram positive Staphylococcus (Table 3) (bioMérieux 
Portugal, 2014). 
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TABLE 2 Content of VITEK® 2 AST gram-negative most used cards for UTI 
diagnosis (bioMérieux Portugal, 2014) 
AST-GN26 AST-GN86 AST-N113 
Ampicillin AMX-CA Ampicillin 
AMX-CA Ampicillin AMX-CA 
Pip/tazo Cefazolin Cefuroxime 
Cefalotin Cefepime Cefotaxime 
Cefuroxime Ceftazidime Ceftazidime 
Cefpodoxime Ceftriaxone Cefepime 
Ceftazidime Cefuroxime Cefoxitin 
Cefotaxime Ciprofloxacin Imipenem 
Cefepime Ertapenem Ertapenem 
Cefoxitin 
ESBL 
Confirmation Test 
Amikacin 
Meropenem Gentamicin Gentamicin 
Amikacin 
Imipenem 
(new formula) 
Tobramycin 
Gentamicin Nitrofurantoin Ciprofloxacin 
Norfloxacin Tetracycline Nitrofurantoin 
Ciprofloxacin Tobramycin TMP-SMX 
Nitrofurantoin TMP-SMX Fosfomycin 
TMP-SMX ------------------------ 
ESBL 
Confirmation Test 
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TABLE 3 Content of VITEK® 2 AST Gram Positive (GP) most used cards for UTI diagnosis 
(bioMérieux Portugal, 2014) 
AST-P586 
(Streptococcus and 
Enterococcus) 
AST P619 
(Staphylococcus) 
Benzilpenicillin Benzilpenicillin 
Ampicillin Oxacillin 
Cefuroxime Vancomycin 
Imipenem Teicoplanin 
Vancomycin Daptomycin 
Teicoplanin Gentamicin 
Streptomycin High Conc. Levofloxacin 
Gentamicin High Conc. Moxifloxacin 
Moxifloxacin Tetracycline 
Levofloxacin Tigecycline 
Tetracycline Eritromicin 
Tigecycline Clindamycin 
Clindamycin Mupirocin 
Quinopristina/Dalfopristina Linezolid 
Linezolid Rifampicin 
Nitrofurantoin Fusidic acid 
TMP-SMX Fosfomycin 
------------------------ NIT 
------------------------ TMPSMX 
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4. TREATMENT OF UTI 
The aim of antimicrobial UTI treatment is the eradication of the current 
microbial infection by applying effective antimicrobial therapy. To relief from 
recurrence and minimize collateral damages, it is strongly advised to whenever 
possible avoid the empirical treatment and perform the antimicrobial susceptibility 
testing. 
4.1. EMPIRICAL TREATMENT 
The early treatment of UTI is crucial to reduce the rate of morbidity, empirical 
antimicrobial therapy guided by local resistance rates should be the primary influence 
on clinician’s choices (Rodrigues, et al., 2011; Barber, Norton, et al., 2013; Linhares, et 
al., 2013). 
The WHO Global Strategy recommends that the choice of empirical treatment 
should be guided by local or national resistance surveillance data, in the absence of 
community regional level surveillance study. Also the local surveillance data should be 
used to guide the drugs management, educate prescribers and guide infection control 
policies. But unfortunately, there are few publications about the main uropathogens in 
the community-acquired UTI and their antimicrobial resistance profile, when 
compared with UTI acquired at hospital level (WHO, 2001; Girard, et al., 2002; WHO, 
2014) 
The Infectious Diseases Society of America (IDSA) Practice Guidelines in 
collaboration with European Society for Microbiology and Infectious Diseases 
(ESCMID) and European Association of Urology (EAU) recommends as first-line therapy 
of U-UTI, fosfomycin due to minimal resistance and propensity for collateral damage 
(Gupta, et al., 2011). Ciprofloxacin is suggested as an effective treatment, but among 
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men the treatment should be extended to 10-14 days (Roriz-Filho, et al., 2010). 
Nitrofurantoin is also an appropriate choice for therapy due to minimal resistance and 
secondary effects (Gupta, et al., 2011).  
The second-line therapy recommended is fluoroquinolones, which  contain 6-
fluoro substituents when compared to quinolones and it is highly efficacious in 3-day 
regimens, but have a propensity for collateral damages and resistance, so they should 
only be used if sensitivity testing is performed (Rowe, et al., 2013). The β-lactam 
agents are appropriate choices for therapy when other recommended agents cannot 
be used, because of their inferior efficacy and more adverse effects. Trimethoprim-
Sulfamethoxazole (TMP-SMX) in spite of being widely diffused in the international 
guidelines should be based on AST and only prescribed if local resistance rates of 
uropathogens do not exceed 20%, due to its high resistance rates in E. coli bacterium 
(Linhares, et al., 2013). According to the 1999 guidelines, amoxicillin or ampicillin 
should not be used for empirical treatment given the relatively poor efficacy and the 
very high prevalence of resistance to these agents worldwide (Gupta, et al., 2011) 
In placebo-controlled studies of U-UTI spontaneous clinical cure rate was from 
25% to 42%, it was significantly higher compare to symptomatic and bacteriological 
cure rates, however the patients treated with antibiotic therapy had a better 
prevention of reinfection (Wagenlehner, et al., 2011).  
4.2. EXCEPTIONAL TREATMENT 
4.2.1. CHILDHOOD RECOMMENDED TREATMENT 
Children with U-UTI are likely to respond to amoxicillin, sulphonamides, TMP-
SMX or cephalosporins, due to their good concentration in the lower urinary tract 
(WHO, 2005). 
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4.2.2. PREGNANCY RECOMMENDED TREATMENT 
In pregnant women, treatment of UTI deserves special attention because of the 
perinatal risks involved. During pregnancy treatment is mandatory and the AST should 
guide the treatment rather than empirical treatment (Calderón-Jaimes, et al., 2013; 
Kapoor, et al., 2012).  
The first-line antibiotics include all β-lactam agents, nitrofurantoin. Second-line 
antibiotics include fosfomycin, trimethoprim (TMP) and the fluoroquinolones, and 
should never be considered during pregnancy antibiotics such as sulphonamides, 
chloramphenicol and tetracycline (Roriz-Filho, et al., 2010; Kapoor, et al., 2012).  
In the first trimester of pregnancy, TMP and fluoroquinolones cannot be 
considered because they affect the normal growth and formation of the foetus. 
Nitrofurantoin is restricted during the last few weeks due to the risk of haemolytic 
anaemia of foetus or neonate (Kapoor, et al., 2012). 
4.2.3. DIABETES RECOMMENDED TREATMENT  
For DA-UTI patients are recommended two weeks (7-14 days) of oral 
antimicrobial therapy and hyperglycaemic control (Mnif, et al., 2014). Fosfomycin, 
TMP-SMX and nitrofurantoin are safe and effective antimicrobial methods to cure and 
prevent UTI in patients with DM, and fosfomycin is associated with rarely recurrence 
of UTI (Ruxer, et al., 2007). 
Antibiotic treatment of ASB significantly increases the risk of adverse events 
without significant clinical benefit, and also increases resistance (SIGN, 2012). However 
ASB is common in women with DM, and if left untreated, it may lead to renal 
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functional impairment, so the clinicians must measure the cost-benefit according to 
each patient criteria (Grabe, et al., 2014). 
4.2.4. ELDERLY RECOMMENDED TREATMENT 
TMP-SMX should have the preference for treatment of UTI in old-aged (Rowe, 
et al., 2013). Among elderly males it is recommend the prostate examination and 
antimicrobial sensibility test (AST) (Roriz-Filho, et al., 2010). 
Nitrofurantoin has low resistance rates in E. coli, although other 
Enterobacteriaceae species are more common in elderly and may have intrinsic 
resistance to nitrofurantoin. In addition, this antimicrobial is contra-indicated in 
patients with chronic kidney disease (Rowe, et al., 2013).  
5. ETIOLOGY  
The literature is unanimous, E. coli is the most common UTI bacterium. This 
bacterium is responsible for 75% to 95% of community-acquired infections and for 
50%-60% of the hospital-acquired UTI (Roriz-Filho, et al., 2011; Gilbert, et al., 2013; 
Landry, et al., 2014; Nicolle, 2014). The uropathogenic Escherichia coli (UPEC) is known 
to invade urothelium cells and form quiescent intracellular reservoirs (QIRs). It is 
thought that QIRs may provide a source for bacterial persistence and R-UTI (Hickling, 
et al., 2013) 
Other significant common bacteria that can cause UTI are Staphylococcus 
saprophyticus, Staphylococcus epidermidis, also other Enterobacteriaceae, such as 
Proteus mirabilis, Klebsiella and Providentia species. Gram-positive organisms, like 
methicillin-resistant Staphylococcus aureus and Enterococcus, are less common overall, 
but are seen with increasing frequency in healthcare settings and in adults with chronic 
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indwelling (Roriz-Filho, et al., 2010; Al-Badr, et al., 2013; Gilbert, et al., 2013; Rowe, et 
al., 2013). 
For susceptible subpopulations, such as DM patients, the incidence of Klebsiella 
spp and Streptococcus sp infections are more common. However Pseudomonas sp 
infections are more common in chronically-catheterised patients (Al-Badr, et al., 2013). 
In the C-UTI patients and R-UTI are very frequent the appearance of multidrug 
resistant E. coli with extended spectrum β-lactamases (ESBL), which difficult the 
treatment (Roriz-Filho, et al., 2010). For men, coagulase-negative staphylococci are 
also common, in addition to gram-negative bacilli and Enterococcus sp and Proteus 
mirabilis (Nicolle, et al., 2005). 
6. UROPATHOGEN RESISTANCE TO ANTIMICROBIALS 
The emergence of antimicrobial resistance is a growing problem in medicine 
worldwide (WHO, 2001). The consumption and misuse of antimicrobials are directly 
related to the increased of bacteria resistance, infected patients morbidity and 
mortality, and consequently to the rising of health-care costs (Edlin, et al., 2014; 
Landry, et al., 2014).  
The nosocomial ASB constitutes a major pool of antibiotic-resistant strains of 
pathogens (Parida, et al., 2013). Multi-resistant gram-negative bacteria accounted for 
a higher number of nosocomial infections than resistant gram-positive bacteria (Ott, et 
al., 2013).  
In community, in spite of being well known that excessive use of antimicrobials 
compromise its efficacy and lead to its resistance, the continuous antibiotic 
prophylaxis therapy is usually used as an effective measure to prevent UTI (Kapoor, et 
al., 2012).  
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E. coli resistance rates have been reported to ampicillin (39-45%), TMP-SMX 
(14-31%), nitrofurantoin (1.8-16%) and fluoroquinolones (0.7-10%) (WHO, 2005). 
According to WHO in the Global Report on Surveillance, the E.coli is resistant to the 3rd 
generation of cephalosporins and fluoroquinolones and also multidrug resistant 
Klebsiella spp (Girard, et al., 2002; WHO, 2014). The ciprofloxacin is in continuous 
decrease for urine isolates from outpatients (from 90% to 88%) and inpatients (from 
85% to 82%) (Landry, et al., 2014). Among C-UTI patients and R-UTI it is very common 
the appearance of E. coli with extended spectrum β-lactamases (ESBL), which implies a 
difficult treatment with broad-spectrum antibiotic (Roriz-Filho, et al., 2010). Even in 
childhood antimicrobial resistance is alarming. Edling and his colleagues reported in a 
study about antimicrobial resistance in paediatric urology that in 2009 TMP-SMX 
resistance rates for E. coli pediatric UTI increased in both sexes, boys (from 23% up to 
31%) and girls (from 20% up to 23%) (Edlin, et al., 2014).  
TMP-SMX is widely diffused in international guides, however, they should only 
be prescribed after antimicrobial sensibility tests and not as an empirical treatment, 
due to its high rates of resistance in E. coli isolates (Roriz-Filho, et al., 2010). 
Fluoroquinolones have played an important role in the treatment of infectious disease, 
with their wide spectrum of activity, convenient dosing, and good patient tolerability 
(Landry, et al., 2014). 
6.1. CLASSES AND ANTIMICROBIAL AGENTS 
Antibiotics were discovered in the middle of the 19th century and soon after 
the discovery of penicillin a number of treatment failures with some bacteria, such as 
staphylococci, which were no longer sensitive to penicillin (Byarugaba, et al., 2009).  
Over the years, the continued use of various antimicrobial agents lead to the 
development of bacteria resistance mechanisms (Giedraitienė, et al., 2011). The 
multidrug resistance emergence contributes to a global economic and health-care 
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crisis, listed by the World Health Organization as one of the top 3 threats to global 
public health (Brooks, et al., 2014). And the main problem is the increasing resistance 
of antibiotic resistance while the number of new antibiotics is decreasing (Figure 5). 
 
FIGURE 5  Antibiotic resistance is increasing while the number of antibiotics is 
decreasing. Adapted from Brooks (2014).  
The antimicrobial agents can be classified based on the cellular components or 
system they affect, such as: interference with cell wall synthesis, inhibition of protein 
synthesis, interference with nucleic acid synthesis, and inhibition of a metabolic 
pathway (Tenover, 2006). In addition if they induce cell death (bactericidal drugs) or 
only inhibit cell growth (bacteriostatic drugs). According to the spectrum of activity can 
be also classified as: broad spectrum, when effective a variety of gram negative or 
gram positive bacteria; narrow spectrum, when effective only against gram negative or 
gram positive (Kohanski, et al., 2010) (Table 4). 
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TABLE 4 Antimicrobials classification and targets (bioMérieux, Inc, 2008; Range, 
et al., 2007). 
Class Substance Target 
β-lactam Ring Penicillins • Ampicillin 
• Amoxicillin 
These semi-synthetic antibiotics are bactericidal. 
Responsible for   the inhibition of peptidoglycan 
synthesis from the cell wall and the autolytic 
activation, which will determine the lyses   and 
posteriori death. 
1st Generation 
Cephalosporins 
• Cefalotin Good Gram-positive activity and relatively modest 
Gram-negative activity. Their target is the cell wall 
lysis. 
2nd Generation 
Cephalosporins 
• Cefaclor 
• Cefuroxime 
• Cefoxitin 
Better Gram-negative coverage, however less 
Staphylococcal activity. Their target is the cell wall 
lysis. 
3rd Generation 
Cephalosporins 
• Cefotaxime  
• Cefixime 
• Ceftazidime 
Bactericidal action after the linkage with the 
cytoplasmic membrane. Wide spectrum of action, 
good activity against Gram-negative and less active 
against Gram-positive. 
Carbapenems • Imipenem Synthesis inhibition of the cell wall. A broad 
spectrum of action. Wide diffusion in the body, 
especially in the cerebrospinal fluid. 
  • Clavulanic 
Acid 
β-lactamase1 enzymatic inhibitor, have weak or poor 
antibacterial activity alone. Should be used in 
association with β-lactams. 
Quinolones • Ciprofloxacin 
• Levofloxacin 
Interfere with the bacterial DNA synthesis, blocking 
the twisting of the strands of DNA to form double-
stranded, inhibitor of the DNA-girase. Bactericidal 
action. 
Aminoglycosides • Gentamicin 
• Tobramycin 
• Amikacin 
Inhibitors of protein synthesis, their penetration 
depends on the active transportation of oxygen, thus 
have a slow rate against anaerobic microbial. 
Therapeutic drug monitoring is mandatory to control 
side effects. Hospital use only, bactericidal action. 
Macrolides • Eritromicin Inhibitor of the protein synthesis by binding to the 
50S subunit of bacterial ribosomes. 
Tetracyclines • Tetracycline Inhibitor of protein synthesis in both Gram-positive 
and Gram-negative bacteria. It has a bacteriostatic 
action. 
Glycopeptides  • Vancomycin  Bactericidal for Gram-positive only. Their complex 
chemical structure also Inhibit the cell wall synthesis, 
but at a different site than the β-lactam agents. 
Good diffusion in all tissues and high toxic effects: 
ears and kidneys. 
Lincosamides • Clindamycin Inhibits the synthesis of proteins, similar to 
chloramphenicol and macrolides. 
Fosfomycins  Inhibition of the cell wall synthesis at a stage earlier 
than the penicillins or cephalosporins. 
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6.2. MECHANISMS OF RESISTANCE  
In order to survive, the bacteria develop mechanisms that enable them to 
respond to selective pressure exerted by various environments and competitive 
challenges. Antimicrobial resistance is a natural biological phenomenon and is often a 
consequence of microbial adaptation to antimicrobials exposure (Byarugaba, et al., 
2009). 
Different antimicrobials have different spectrum of action against the microbes. 
Some are specific for gram positive while other are specific for gram negative, no 
antimicrobial is effective to all microbes (Vishwas, et al., 2012) (Table 5).  
TABLE 5 Resistance mechanisms found in common bacteria pathogens (Poole, 
2007; Vishwas, et al., 2012; Mandell, et al., 2004) 
Bacteria Method of resistance Antimicrobials 
Escherichia coli Active efflux system Tetracyclines  
Klebsiella 
pneumoniae 
Enzymatic inhibition 
Alteration of ribosomal target sites 
Β- lactams 
Aminoglycosides 
 
Pseudomonas 
aeruginosa 
Enzymatic inhibition 
Active efflux system 
Β- lactams 
Aminoglycosides 
Quinolones Tetracyclines 
Trimethoprim 
 
Enterococci 
Alteration of target enzymes 
Altered ribosomal target site mutations 
Enzymatic inhibition 
Alteration of cell-wall precursor targets 
Alteration of ribosomal target sites 
Ampicillin 
Aminoglycosides 
 
Vancomycin 
Linezolid 
 
Streptococcus 
pneumonia 
Alteration of target enzymes 
Alteration of ribosomal target sites 
Protection of ribosomal target sites 
Β- lactams 
Macrolides 
Lincosamides 
Tetracyclines 
Trimethoprim 
Sulfamides 
 
Staphylococcus 
aureus  
Enzymatic inhibition 
Alteration of target enzyme 
Alteration of cell-wall precursor targets 
Penicillin 
MRSA 
GISA 
GRSA 
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Bacteria may be naturally resistant (vertical evolution) by the lack of transport 
system for an antibiotic, the lack of the target of the antibiotic molecule, or the cell 
wall is covered with an outer membrane that establishes a permeability barrier against 
the antibiotic (gram negative).  
Or may develop resistance to antibiotics by mutating existing genes (vertical 
gene transfer). When exposed to unfavourable environmental conditions the bacteria 
enter into a “hypermutable state” model, which the rate of mutations increase from 
10 to 50 up to 10 000 times during a prolonged nonlethal selection of microorganisms. 
This adaptive process is the only and main source of the antibiotic-resistant mutants to 
originate under normal conditions and they are called “adaptive mutations” 
(Giedraitienė, et al., 2011; Vishwas, et al., 2012; Brooks, et al., 2014). 
The acquiring resistance (horizontal gene transfer) beyond spontaneous 
mutation requires either the modification of existing genetic material or the 
acquisition of new genetic material from another source, strain or specie. The 
horizontal gene transfer occurs by many different mechanisms, mobile genetic 
elements including: phages, plasmids and transposons (Giedraitienė, et al., 2011; 
Vishwas, et al., 2012). 
There are at least three possible mechanisms: transduction, (via 
bacteriophages and integrons) occurs when DNA are transferred between two closely 
related bacteria;  transformation (via plasmids and conjugative transposons) is a 
process where parts of DNA are taken up by the bacteria normally present in the 
external environment due to the death and lysis of another bacterium; conjugation 
(via incorporation of chromosomal DNA, plasmids into a chromosome) occurs when 
there is direct cell-cell contact between two bacteria closely related and transfer small 
pieces of DNA (Giedraitienė, et al., 2011; Vishwas, et al., 2012).  
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The transfer of resistance genes is more effective than chromosomal mutation. 
Most plasmids are double-stranded circular DNA whose size may vary from 2–3 kb, 
which encode up to 10% of the host cell chromosome and confer resistance to main 
classes of antimicrobial agents (cephalosporins, fluoroquinolones, and 
aminoglycosides) (Giedraitienė, et al., 2011). 
Transposons can be integrated into plasmids or the host’s chromosome, 
encompass small elements called insertion sequence elements and transposing 
bacteriophages. They have terminal repeat sequences that play a role in 
recombination and recognize a protein (for example, transposase or recombinase) that 
is necessary to insert or remove a transposon from specific genome regions. 
Transposons are transferred by conjugation, transformation, or transduction and 
spread quicker than genes in chromosomes. Conjugative transposons have 
characteristic features of plasmids and can help to transfer endogenic plasmids from 
one microorganism to another (Giedraitienė, et al., 2011). 
When resistance determinants are on plasmids, they will spread quickly within 
the genus or even unrelated bacterial genera. When resistance is associated with 
genes on chromosomes, resistant microorganisms will spread more slowly 
(Giedraitienė, et al., 2011). Also, the presence of low levels of the antibiotic in the 
environment promotes gene transfer.  
The combined effects of fast growth rates to large densities of cells, genetic 
processes of mutation and selection, and the ability to exchange genes, account for 
the extraordinary rates of adaptation and evolution of bacteria (Vishwas, et al., 2007).  
6.3. ANTIBIOTIC STEWARDSHIP 
Bacterial resistance is closely associated with the use of antimicrobial agents in 
clinical practice. Prolonged therapy with antibiotics may lead to the development of 
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resistance in a microorganism that initially is sensitive to antibiotics, but later it can 
adapt gradually and develop resistance to antibiotics (Giedraitienė, et al., 2011). Also, 
the use in nonhuman niches is another important reason for the spread of resistant 
bacteria, such for growth promotion, feed efficiency, and routine disease prevention 
purposes in animal agriculture it is a factor of increasing resistance (IDSA, 2011; 
Giedraitienė, et al., 2011). For example, Salmonella and Campylobacter acquire 
resistance to antibiotics and have transferred antibiotic resistance to natural human 
flora. The E. coli resistance to ciprofloxacin is associated with the use of 
fluoroquinolones in aviculture (Giedraitienė, et al., 2011).  
Some conditions that may promote the acquiring of antimicrobial resistance 
that should be avoided, such as: 
 Exposure to non-lethal levels of antimicrobials; 
 Exposure to bacteria with acquired resistance genes; 
 Over- the-counter purchases without medical supervision; 
 Antimicrobials prescriptions for non-bacterial infections; 
 Antimicrobials self-medication without medical supervision; 
 Growth promotion, feed efficiency, and routine disease prevention in 
animal agriculture without veterinarian prescription; 
Considering the rising of multidrug resistant bacteria, preventative measures 
are required (Byarugaba, et al., 2009). To minimize the medication errors in clinical 
practice were suggested the 10 tips for safe prescribing (National Prescribing Centre, 
2011): 
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1. Keep yourself up-to-date in your knowledge of therapeutics, especially 
for the conditions you commonly see; 
2. Before prescribing, make sure you have all the information you need 
about the patient, including co-morbidities and allergies; 
3. Before prescribing, make sure you have all the information you need 
about the drug(s) you are considering to prescribe, including side effects 
and interactions; 
4. Sometimes the risks of prescribing outweigh the benefits and before 
doing so, think: ‘Do I need to prescribe this drug at all?; 
5. Check computerised alerts in case you have missed an important 
interaction or drug allergy; 
6. Always carefully check prescriptions for errors before signing them; 
7. Involve patients in prescribing decisions and give them the information 
they need in order to take the medicine as prescribed, to recognise 
important side-effects and to know when to return for monitoring; 
8. Have systems in place for ensuring that patients receive essential 
laboratory test monitoring for the drugs they are taking, and that they 
are reviewed at appropriate intervals; 
9. Make sure that high levels of safety are built into your repeat 
prescribing system; 
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10. Make sure you have safe and effective ways of communicating 
medicines information between primary and secondary care, and act on 
medication changes suggested by secondary care clinicians; 
7. PREVENTION 
7.1. PREVENTIVE ANTIMICROBIAL MEASURES 
Appropriate prescribing is essential to improve patient outcomes and to help 
prevent the emergence of resistant organisms. Risk versus benefits should be weighed 
carefully before using antibiotics. Poor empiric prescribing practices, lack of urine 
testing, and nonselective use of prophylaxis exacerbate this problem. It is also strongly 
recommended some practice patterns, such as: urine antimicrobial susceptibility 
testing in order to only treat when indicated; high selective application of antibiotic 
prophylaxis; local surveillance programs with inpatient versus outpatient data should 
be implemented (Edlin, et al., 2014). 
The adoption of conservative measures by subpopulations at increased risk is 
very important to counter the prevalence of community-acquired UTI. Some hygiene 
modifications, such as: limiting of spermicide use; urinating and washing the genitals 
pre- and post-coital; wiping from front to back after toilet and every 3-4 hours; shower 
instead of immersion bath and avoid the perfumed soaps; acquisition of cotton 
underwear instead nylon. These preventive behavioural actions can avoid many 
episodes of R-UTI in the long-term (Kapoor, et al., 2012). 
7.2. PREVENTIVE NON-ANTIMICROBIAL FORMULATIONS 
Prevention strategies for R-UTI in subpopulations with increased risk have been 
studied using non-antimicrobial therapies in place of antibiotic prophylaxis, such as: 
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estrogen replacement therapy, lactobacilli formulation and cranberry formulations 
(SIGN, 2012; Hickling, et al., 2013). 
Estrogen is thought to play an important role in maintaining a low vaginal pH in 
pre-menopausal women. The low estrogen in postmenopausal women promotes 
changes in the vaginal flora and the predominant flora in younger women often 
disappear. This leads to an increase in vaginal pH and promotes colonization of 
uropathogens (Rowe, et al., 2013). The application of intravaginal estrogen, as topical 
vaginal estrogen cream, proved to be effective and safe (Hickling, et al., 2013).  
Oral lactobacilli formulation has been tested as a prevention strategy in 
postmenopausal women with recurrent UTI. The hypothesis was that oral lactobacilli 
may repopulate the vagina with premenopausal vaginal flora, thereby preventing UTI 
(Rowe, et al., 2013).  
The intake of Cranberry products is a non-antimicrobial approach, which has 
been used for prevention and treatment of UTI. Cranberry proanthocyanidin is the 
active ingredient in cranberries that inhibits adherence of P-fimbriated E.coli to the 
bladder epithelium. In contrast, cranberry formulations interfere with certain 
medications and should be taken after medical advice only (SIGN, 2012; Hickling, et al., 
2013; Jepson, et al., 2013; Rowe, et al., 2013).  
Other formulations, such as ascorbic acid (vitamin C) intake to acidify urine and 
make it hostile for bacterial growth, in vitro data suggest a bacteriostatic effect 
(Hickling, et al., 2013). Another example is methenamine salts intake, these salts are 
hydrolysed in the urine to form ammonia and formaldehyde. Formaldehyde is widely 
bacteriostatic and does not allow the development of bacterial resistance. In a study, 
they have compared continuous methenamine hippurate and continuous antimicrobial 
prophylaxis in healthy adult women and found no significant difference between 
prophylactic trimethoprim and methenamine hippurate (Hickling, et al., 2013). 
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Fluid intake, especially water, helps dilute urine and promotes frequently 
voiding, which allows bacteria to be flushed from your urinary tract before an infection 
can begin (Beetz, 2003). Well as the limitation of the intake of substances that irritate 
the bladder epithelium, like caffeine and chocolates may help to prevent UTI (Kapoor, 
et al., 2012). 
8. RESISTANCE AND FUTURE PERSPECTIVES 
The antimicrobial resistance is a global problem that calls for a global response, 
and the implementation of a global strategy and preventive guidelines to slow down 
the antimicrobial resistance is crucial to its success (WHO, 2014). 
The local surveillance implementation is very important to promote effective 
empirical treatments. However, the main clinical diagnostic dilemma persists, the 
distinguishing of symptomatic UTI from ASB and which patients to treat with 
antibiotics (Barber, et al., 2013; Hickling, et al., 2013; Rowe, et al., 2013). 
Future studies to evaluate non-antimicrobial formulations in order to stop the 
increasing resistance rates remain important to prevention of UTI (Barber, et al., 2013; 
Hickling, et al., 2013; Rowe, et al., 2013). Like the implementation of CA-UTI 
prevention guidelines, which should be included into an effective program. Including 
indications of catheter selection, catheter insertion/maintenance and dates of 
insertion and removal should be established. And alternative strategies, such as 
substitution of indwelling urethral catheters for external condom catheters in men, 
and the staff education in health care facilities are essential to minimize the risk of CA-
UTI (Nicolle, 2014).  
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The application of preventive practices and renewed treatment approaches can 
reduce significantly the prevalence of UTI, even as the resistance rates worldwide in 
the future. 
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1. ABSTRACT 
Urinary tract infection (UTI) is the second most common infection in 
community and the most common nosocomial infection worldwide. The main goal of 
this study is to evaluate the predominance of uropathogens responsible for urinary 
tract infection and determine their resistance patterns, in order to assess if the 
recommended empirical treatment is appropriated for this population. Samples were 
collected at Centro Médico da Praça Lda on ambulatory system, in São João da 
Madeira municipality (Aveiro, Portugal) from June 2011 to June 2014. From 4270 
analysed urine samples, 3561 (83%) were from women and only 709 (17%) were from 
men, from 0 to 104 years of age. E. coli was the most frequent uropathogen, followed 
by Klebsiella spp and Enterococcus spp and P. mirabilis. From all data 37% were MDR 
isolates and from these 30.9% were from women and 61.6% were from men. In 
general men were more resistant to antimicrobials than women. From first line drugs 
recommended by EAU to empirical treatment of uncomplicated UTI only 
nitrofurantoin is appropriated for both sexes and ciprofloxacin may be only considered 
to treat women. In the second line antibiotics, ampicillin is not an appropriate drug to 
empirical treatment of uncomplicated UTI, however the antimicrobials AMX-CA and 
TMP-SMX should not be used to empirical treatment of men, due the local high 
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incidence of resistance, over 20% for men. Thus, it is suggested the use of imipenem 
and gentamicin as an alternative to treat both sexes. 
2. INTRODUCTION 
Urinary tract infection (UTI) is the second most common infection in 
community and the most common nosocomial infection worldwide (Al-Badr, et al., 
2013; Ott, et al., 2013; Sujatha, et al., 2014). The episode of UTI is classified as lower 
(bladder, urethra and prostate) or upper (Kidneys) urinary tract infection considering 
the affected organs. Uncomplicated urinary tract infection (U-UTI) occurs in non-
pregnant young women with a normal genitourinary tract. Complicated urinary tract 
infection (C-UTI) was diagnosed in genitourinary tract with structural, functional 
abnormalities or developed in healthcare settings (including catheterized patients) 
(Roriz-Filho, et al., 2010). Recurrent urinary tract infection (R-UTI) results from three 
positive urine cultures during a 12-month period, or two infections during the previous 
6 months and it is mainly caused by reinfection of the same pathogen (Graziottin, 
2014). Symptoms are usually slight in U-UTI or absent in case of asymptomatic 
bacteriuria (ASB). The diagnosis of infection is defined as the presence of two 
consecutive positive urine specimens with the same bacterial strain in quantities equal 
or superior to 105 CFU mL-1 (Rowe, et al., 2013).  
Community-acquired urinary tract infections are mainly uncomplicated, 
colonizing preferably the bladder causing cystitis (Stamm, 2006; Wiles, Kulesus, et al., 
2008). However, some bacteria may ascend through the ureters to the kidneys and 
cause more severe infections such as pyelonephritis (Stamm, 2006; Wiles, et al., 2008). 
Moreover, specific subpopulations are more likely to have UTI, such as, patients with 
catheters, urologic abnormalities, diabetics, immunodeficiency, infants, pregnant 
women and elderly, to these patients UTI can be more severe (Foxman, 2002). 
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Undesirably, there is little knowledge about the main uropathogens and their 
antimicrobial resistance pattern implicated in community-acquired UTI compared with 
UTI acquired at hospital level. The importance of this information is the periodic 
monitoring of the changes over the years, in order to decrease the number of 
therapeutic failures (Linhares, et al., 2013). 
The few studies carried out in the community have shown that uropathogens, 
such as, Escherichia coli (46.4 - 74.2%), Klebsiella spp (6.0 - 13.45%), Proteus spp (4.7 - 
11.9%) and Enterococcus spp (5.3 - 9.54%) are the most prevalent in UTI (Neto, et al., 
2003; Akram, et al., 2007; Correia, et al., 2007; Francesco, et al., 2007; Laupland, et al., 
2007; Pires, et al., 2007;  Mendo, et al., 2008; Costa, et al., 2009; Rahman, et al., 2009; 
Martins, et al., 2010; Nimri, et al., 2010). E. coli has been indicated as the most 
frequent uropathogen involved in the community-acquired UTI (Francesco, et al., 
2007; Laupland, et al., 2007; Mendo, et al., 2008; Costa, et al., 2009) probably because 
it belongs to the normal flora of the human intestine and therefore easily colonize the 
urinary tract.  
According to the European Association of Urology (EAU) the empirical first line 
treatment recommended to acute U-UTI is ciprofloxacin, fosfomycin and 
nitrofurantoin, followed by ampicillin, amoxicillin-clavulanic acid (AMX-CA) and 
trimethoprim-sulfamethoxazole (TMP-SMX) as second line treatment. The European 
Society for Microbiology and Infectious Diseases (ESCMID) recommends as first line 
therapy for acute U-UTI, fosfomycin due to minimal resistance and collateral damage 
(Gupta, et al., 2011). Ciprofloxacin is a suggested as an effective 3-day regiment, while 
men treatment should be extended to 10-14 days (Roriz-Filho, et al., 2010). 
Nitrofurantoin is also an appropriate choice for therapy due to minimal resistance and 
collateral damages (Gupta, et al., 2011).  
The second line therapy recommended the class of β-lactam agents when first 
line recommended agents cannot be used, due to their inferior efficacy and more 
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adverse effects. TMP-SMX in spite of being widely diffused in the international 
guidelines must be based on AST and it should only be prescribed if local resistance 
rates of uropathogens do not exceed 20% (Grabe, et al., 2014). According to the 1999 
Uncomplicated Urinary Tract Infection Guidelines by the IDSA, AMX or AMP should not 
be used for empirical treatment given the relatively poor efficacy and the very high 
prevalence of resistance to these agents worldwide (Gupta, et al., 2011). 
The high rates of resistance among pathogenic bacteria suggest the failure of 
the past preventive guidelines to slow down the antimicrobial resistance (WHO, 2001; 
Francesco, et al., 2007; Koningstein, et al., 2013; Linhares, et al., 2013, WHO, 2014). 
The empirical treatment, used in an early disease phase to decrease the rate of 
morbidity, should be guided by national resistance surveillance data, in the absence of 
surveillance community studies at regional level (WHO, 2001; Linhares, et al., 2013; 
WHO, 2014). The surveillance should be continuous, the bacterial resistance patterns 
change over the time. In order to administer an appropriate empirical therapy it is 
crucial to know not only the main bacteria usually involved in the UTI but also their 
respective antibiotic resistance patterns. This surveillance procedure controls the 
increase of antimicrobial resistance and the spread of resistant bacterial strains that 
represent a public health problem worldwide.  
The goal of this study is to evaluate the predominance of uropathogens 
responsible for urinary tract infection and their resistance patterns, in North Aveiro 
(Portugal) between 2011 and 2014 in order to assess if the empirical recommended 
treatment of UTI is appropriate for this population. 
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3. METHODS 
3.1. DATA SAMPLES 
All the samples were collected in the ambulatory system from June 2011 to 
June 2014 at Centro Médico da Praça Lda, located in São João da Madeira municipality, 
district of Aveiro in the north-western region of Portugal. Positive UTI samples at the 
reception were registered with code and associated to the patient’s process number. 
To build the database was registered the gender, age, bacterial strain and the 
corresponding antimicrobial susceptibility testing (AST) from the VITEK© 2 
(bioMérieux SA) report. This study was approved by the clinical analysis laboratory 
Centro Médico da Praça Lda. 
3.2. SAMPLING 
First morning urine samples (not less than 4 hours storage in bladder) were 
collected by the patients after the daily hygiene at home. The first and final urine was 
rejected, only the midstream portion was collected to a sterile urine container to avoid 
contaminations. Samples were transported in their primary containers and stored at 
4°C until they can be processed (European Confederation of Laboratory Medicine, 
2000). 
3.3. URINALYSIS  
In the laboratory, samples were triaged and 10-15 mL from the sterile 
containers were transferred into examination tubes to the dipstick analysis, to nitrite 
and leucocyte esterase detection. Then the examination tubes were centrifuged at 
1500 rpm for 5 minutes to the microscopic analysis. 
One microliter of urine sample was inoculated with a disposable plastic loop on 
CLED media or chromID™ CPS® plates (bioMérieux) and incubated at 37 °C in aerobic 
atmosphere for 18 hours. These culture media allow direct presumptive identification 
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of E. coli, Proteus spp and Enterococcus spp having in consideration the sizes, colours 
and shapes of the colony-forming units (CFU) (bioMérieux SA, 2013). After incubation, 
all the negatives cultures, bacteria growth inferior to 103 CFU/mL, were excluded. 
Urine culture was defined as positive if bacterial growth was equal or superior to 105 
CFU/mL, with a maximum of 2 isolated species. Samples were considered 
contaminated if 3 or more different colonies grown in the culture medium, these 
samples were classified as “polymorph flora” and a second sample was requested from 
the patient. Bacteriuria was defined when bacterial growth was inferior to 105 CFU/mL 
and, in these cases, it was only preformed the identification (ID) and antimicrobial 
sensibility test (AST) for pregnant women or children. 
3.4. IDENTIFICATION OF BACTERIAL ISOLATES 
Identification was performed by the VITEK© 2 ID card, after a gram stain to 
differentiate bacterial species into gram-positive or gram-negative. The isolates were 
inoculated in a saline suspension, with a density between 0.5-0.65 in McFarland scale. 
According to the colonies characteristics, it was chosen the VITEK® 2 GN ID Card to 
identify lactose fermenting and non-fermenting gram-negative bacilli, or VITEK® 2 GP 
ID Card to identify gram-positive bacteria (bioMérieux SA, 2014 b). The VITEK® 2 ID 
cards were introduced into the saline suspension and incubated at 36 °C in the VITEK® 
incubator, and the results were available within 10 hours (Funke, et al., 2004; 
bioMérieux SA, 2014 b). 
3.5. ANTIMICROBIAL SUSCEPTIBILITY TEST (AST) 
The AST was performed with VITEK® 2 AST Card. The VITEK® 2 AST-GN26 
(Portuguese card for urine samples) and VITEK® 2 AST-N113 to gram negative bacteria 
with resistance to the majority of the antibiotics from the VITEK® 2 AST-GN26; VITEK® 
2 AST-P586 to gram positive Enterococcus spp and Streptococcus spp and VITEK® 2 AST 
P619 to Gram positive Staphylococcus spp (bioMérieux Portugal, 2014) were used. 
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Three millilitres of a commercial saline (0.45%) liquid medium, recommend for 
procedures that require the use of a diluent with a VITEK® system, were prepared for 
each respective ID card suspension, based on the established concentrations (Thermo 
Fisher Scientific Inc., 2008; Thermo Fisher Scientific Inc., 2009). From gram-negative 
(GN) suspensions 147 µl of the VITEK® ID suspension were taken and from gram-
positive (GP) 270 µl of the VITEK® ID suspension were used. Both suspensions, ID cards 
and AST cards were introduced into respective saline suspensions and incubated at 36 
°C in the VITEK® incubator for 10 hours (Funke, et al., 2004; bioMérieux SA, 2014 a). 
The AST results were validated by advanced expert system (AES) program, 
which follows the European committee on antimicrobial susceptibility testing 
(EUCAST). The phenotypic antimicrobial susceptibility testing determination depends 
on the minimal inhibitory concentration (MIC) breakpoints. Based on breakpoints, 
bacteria were grouped into three categories: susceptible, intermediate and resistance. 
Meanwhile, the ESBL-confirmation test was also performed (bioMérieux SA, 2014 a; 
Stokkou, et al., 2014) 
3.6. STATISTICAL ANALYSIS 
The data base was done using the Microsoft Excel program and treated using 
the Statistical Package for the Social Sciences (SPSS) 16.0 for Windows. The normality, 
homogeneity and independence of the variants were checked before analysis. Since 
the data failed the normality assumptions, non-parametric methods were used to 
detect significant differences. Mann–Whitney U test was used to evaluate differences 
between genders. The Kruskal-Wallis test was used to evaluate the age and study 
period influence in the UTI incidence. The Chi-square test was used to evaluate the 
incidence of isolates into the age groups. The significant level established was p>0.05. 
The main bacteria responsible for UTI, such as, E.coli, Enterococcus spp, Klebsiella spp, 
P. mirabilis, P. aeruginosa, Staphylococcus spp and S. agalactiae were identified as 
responsible for at least 1% of the study infections (representing 93.5% of the total 
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urinary tract infections). The remaining bacteria were grouped and classified as “other 
bacteria” (representing 6.5% of the total infections) and were included the 
uropathogens: Acinetobacter baumannii, Burkholderia cepacia, Citrobacter spp, 
Enterobacter spp, Hafnia alvei, Morganella spp, Proteus spp, Providencia spp, 
Pseudomonas spp, Raoultella spp, Salmonella enteretidis, Serratia spp, Shigella spp, 
Sphingomonas paucimobilis, Yersinia enterocolitica. The resistant uropathogens to 
three or more antimicrobial classes were considered multi-drug resistant (MDR). 
4. RESULTS 
4.1. CHARACTERIZATION OF THE UTI SAMPLES 
From 4270 analysed urine samples, 3561 (83%) were from women and only 709 
(17%) were from men. The age range varied from 0 to 104 with an average of 61 years 
of age. The average age for women was 59 years of age and for men 68 years of age. 
The incidence of UTI increased with the age (Chi-square, p<0.05), being the elderly (≥ 
65) age group the most affected with 2219 (52%) urine samples (78,1% corresponding 
to women and 21,9% corresponding to men), followed by adults (35-64) with 1381 
(32.3%) samples (87% corresponding to women and 13% corresponding to men), 
young adults with 516 (12.1%) samples (97,9% corresponding to women and 2,1% 
corresponding to men), adolescents (13-18) with 53 (1.2%) samples (94,3% 
corresponding to women and 5,7% corresponding to men), and the last age group, 
children (0-12) with 101 (2.4%) samples (70,3% corresponding to women and 29,7% 
corresponding to men) (Figure 1a). However, between children and the adolescent 
groups a 1% decrease in women was observed, the decreasing tendency was also 
observed between children and the young adults groups (2% to 0%, respectively) in 
men (Figure 1a). 
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In general, women was the most affected in all age groups and the incidence of 
UTI increased with the patient’s age (Figure 1a). The largest gender differences among 
age groups occurred in elderly, adults and young adults (differences about 30%, 24% 
and 12%, respectively) (Figure 1b). 
 
FIGURE 1 a - The incidence of UTI by age groups considering the genders; d 
Significant statistically differences between age groups distribution (Chi-square, p < 
0.05); Percentage in relation to all UTI episodes (N=4270). b – d Significant statistically 
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4.2. BACTERIAL IMPLIED IN UTI 
The predominant uropathogens were E. coli (63.8%), Klebsiella spp (11.8%), 
Enterococcus sp (6.8%), P. mirabilis (5.6%), Staphylococcus spp (2.4%), P. aeruginosa 
(1.9%) and S. agalactiae (1.2%). The isolates under 1% of UTI classified as “other 
bacteria” correspond to a 6.5% of the samples (Table 1). 
TABLE 1 Frequency of isolates responsible for at least 1%; N – frequency of 
isolates; Total % - percentage of isolates in relation to N; Female (%) - percentage of 
isolates in relation to n women; Male (%) -  percentage of isolates in relation to n men. 
Order Bacteria 
Total (%) Female (%) Male (%) 
N = 4270 n = 3561 n = 709 
1º  Escherichia coli 2723 63.8 67.80 43.40 
2º  Klebsiella spp 502 11.8 11.30 14.00 
3º  Enterococcus spp 290 6.8 6.20 9.60 
4º  Proteus mirabilis 240 5.6 4.60 10.70 
5º  Staphylococcus spp 103 2.4 2.20 3.40 
6º  Pseudomonas aeruginosa 83 1.9 1.30 5.10 
7º  Streptococcus agalactiae  50 1.2 1.30 0.70 
… Other Bacteria 279 6.5 5.20 13.10 
 
The main bacteria implicated in women UTI was statistically different from the 
main bacteria implicated in men UTI (Mann-Whitney U test, p< 0.05). E. coli was the 
bacterium most implicated in both genders UTI, however its incidence was higher in 
women, 67.8%, than in men, 43.4% (Table 2). To the remaining bacteria in women, the 
second most implicated bacterium was Klebsiella spp (11.3%) followed by 
Enterococcus sp (6.2%), P. mirabilis (4.6%), Staphylococcus spp (2.2%), P. aeruginosa 
(1.3%) and S. agalactiae (1.3%), other bacteria represented 5.2% of the isolates. For 
men, the second uropathogen most frequent was Klebsiella spp (14%) followed by P. 
mirabilis (10.7%), Enterococcus sp (9.6%), P. aeruginosa (5.1%), Staphylococcus spp 
(3.4%) and S. agalactiae (1.3%), other bacteria represented 13.1% of the isolates 
(Table 2). 
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The analysis of aetiology has shown statistical significant differences between 
age groups (Kruskal-Wallis test, p<0.05). An increasing incidence of Klebsiella spp over 
the age groups was reported. The incidence of P. mirabilis was substantially higher in 
children compared to the remaining age groups. Staphylococcus spp and Enterococcus 
spp had higher incidence in adolescence and young adults compared to the remaining 
age groups. For young adults and adults, E.coli was responsible for more than half of 
the UTI infections (Figure 2). 
 
FIGURE 2 Study of aetiology of UTI isolates by age groups considering the 
genders; d significant differences between age groups (Kruskal-Wallis test, p<0.05); d 
Significant statistically differences between sexes (Mann-Whitney U test, p< 0.05). 
Significant differences in the UTI main bacteria were observed throughout the 
study period (Kruskal-Wallis test, p< 0.05). During the study period the incidence of E. 
coli has varied slightly between 60.8%-66.0%, it was always responsible for more than 
half of the UTI episodes (Figure 3a). The incidence of Klebsiella spp has shown a 3% 
decrease over the study period (variation 14.8%-10.7%). However, Enterococcus spp 
has registered a 5.3% increase during the same period (variation 4.4%-9.7%). The 
incidence of P. aeruginosa (variation 1.7%-2.2%), Staphylococcus spp (variation 2.1%-
2.6%), S. agalactiae (variation 0%-2.2%) and P. mirabilis (variation 4.9%-6.6%) were 
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irregular but almost constant over the study period (Figure 3b). Significant gender 
differences in the main bacteria responsible for UTI were observed during the study 
period into the years 2011 and 2013 (Mann–Whitney U test, p <0.05) (Figure 4). 
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FIGURE 3 Etiology over the study period; a Percentage scale; b Logarithmic scale; 
d significant statistical differences between the main bacteria throughout the study 
period (Kruskal-Wallis test, p< 0.05). 
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FIGURE 4 Etiology over the study period considering the genders; d etiology 
significantly statistically differences between genders into the years 2011 and 2013 
(Mann-Whitney U test, p< 0.05). 
4.3. ANTIMICROBIAL RESISTANCE PATTERN OF THE MAIN BACTERIA IMPLIED IN UTI 
Gram-negative bacteria, on average, presented high resistance to penicillins, 1st 
generation cephalosporins, 2nd generation cephalosporins, fosfomycin, nitrofurantoin 
and TMP-SMX (Table 2). E. coli has shown high resistance to ampicillin (47.9%) and 
TMP-SMX (25.1%) for both genders. Klebsiella spp presented high resistance to 
ampicillin (98.6%), 1st (22.9-23.1%) and 2nd generation (25.3%) cephalosporins, 
ciprofloxacin (25.3%), fosfomycin (51.5%) and nitrofurantoin (28.9%). P. mirabilis 
presented high rates of resistance to nitrofurantoin (97.4%), TMP-SMX (39.3%), 
ampicillin (48.1%), fosfomycin (34.9%), ciprofloxacin (30.4%). P. aeruginosa presented 
high rates of resistance to TMP-SMX (95.8%), ampicillin (95.6%), AMX-CA (93.3%), 
fosfomycin (81.0%), nitrofurantoin (95.7%), cefalotin (93.3%), cefixime (91.3%), 
cefotaxime (88.9%) (Table 2). 
Gram-positive bacteria, on average, presented high resistance to 
cephalosporins 2nd generation, carbapenems, ciprofloxacin, eritromicin, tetracycline 
and clindamycin. Enterococcus sp presented the highest rates of resistance to TMP-
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SMX (94.8%), cefaclor (94.3%), cefuroxime (94.4%), clindamycin (92.7%) and 
tetracycline (80.9%). Staphylococcus spp showed the highest resistance to cefotaxime 
(100%), cefuroxime (85.7%), imipenem (83.9%), cefaclor (82.5%) and fosfomycin 
(80.0%). S. agalactiae showed high resistance to tetracycline (87.8%), ciprofloxacin 
(100%), clindamycin (51.1%) and eritromicin (46%) (Table 2). 
The other bacteria group, on average, showed the highest resistances to 
tetracycline (100%), vancomycin (100%), linezolid (100%), ampicillins (87.5%), cefalotin 
(72.7%) and AMX-CA (60.7%) (Table 2). 
The average resistance presented by bacteria implicated in UTI was statistically 
different (Mann-Whitney U test, p< 0.05) between genders. E. coli, Klebsiella spp, P. 
mirabilis and Staphylococcus spp, were the bacteria responsible for the major 
difference between genders. No differences in the resistance patterns between 
women and men were observed for S. agalactiae and the other bacteria group (Table 
2). 
Considering all the uropathogens isolated, on average, they were resistant to 3 
antimicrobials and to 2 antimicrobial of different classes of drug. Considering the 
isolates from both genders: the isolates from women were resistant on average to 2 
antimicrobials and to 2 antimicrobial classes of drugs; the isolates from men were 
resistant, on average, to 5 antimicrobials and to 4 antimicrobial classes of drug. 
The bacterial resistance changed significantly over the study period (Kruskal-
Wallis test, p < 0.05) (Figure 5). The bacterial resistance to penicillins, 2nd and 3rd 
generation cephalosporins, lincosamides, fosfomycins, carbapenems and macrolides 
decreased. However, for S. agalactiae was observed an increase in resistance to the 
antibiotics tetracyclines, glycopeptides, lincosamides and macrolides over the study 
period. The pattern of resistance of P. aeruginosa was different from that of the other 
gram-negative (E.coli, P. mirabilis, Klebsiella spp) from 2011-2013 for 1st to 3rd 
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generation cephalosporins, fosfomycins and sulfamides. The resistance of E coli was 
constant throughout the study period to each antimicrobials tested (Figure 5). 
The pattern of bacterial resistance to antibiotics was significantly different 
among age groups (Kruskal-Wallis test, p<0.05). The pattern of resistance of P. 
aeruginosa was different from that of the other gram-negative (E. coli, P. mirabilis, 
Klebsiella spp), namely in the group of young adults, for penicillins, 1st to 3rd generation 
cephalosporins, fosfomycins, carbapenems, quinolones, nitrofurans and sulfamides 
(Figure 6). 
Since 63.8% of the infections were caused by E. coli and 36.2% by the remaining 
bacteria, resistance were achieved through the weighted average. The weighted 
average was calculated through arithmetic average, but having in to account the 
incidence of each bacterium. The values of antimicrobial resistance of each bacterium 
were multiplied by its incidence.  
Considering the first line treatment recommended by EAU, the weighted 
average for ciprofloxacin was > 20%, exceeding the recommended value. However, 
considering only the women, the resistance was < 20%. For fosfomycin the resistance 
was > 20% for isolates of both genders. Contrarily, the resistance to nitrofurantoin was 
< 20% for isolates of both genders.  
Considering the second line treatment recommended by EAU, the weighted 
average resistance to ampicillin for both sexes was > 20%, higher than the value 
recommended value by EAU. The weighted average resistance to TMP-SMX and AMX-
CA was > 20% considering all the isolates but it was < 20% when only the women were 
considered. The resistance to imipenem and gentamicin was < 20% for both genders, 
below the recommended value of the EAU (Table 3). 
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TABLE 2 Arithmetic averaged of antimicrobial resistance in the main bacteria for women and men; TMP-SMX, trimethoprim-
sulfamethoxazole; AMX-CA, amoxicillin-clavulanic acid; n total number of resistant bacteria; F – Female; M- Male; ● Higher than the 
recommendable value (>20%). 
   E. coli (%) Klebsiella spp (%) P. mirabilis (%) P. aeruginosa (%) 
Class Antimicrobial N = 4270 n = 2723 F = 2415 M =308 n = 502 F = 403 M = 99 n = 240 F = 164 M = 76 n = 83 F = 47 M = 36 
Penicillins 
Ampicillin 3028 47,9% 45,8% 66,5% 98,6% 98,3% 100,0% 48,1% 46,8% 51,0% 95,6% 95,5% 95,7% 
AMX-CA 3778 11,4% 10,3% 19,8% 18,1% 13,3% 37,4% 17,3% 14,9% 22,4% 93,3% 95,5% 91,3% 
Cephalosporins 1st G Cefalotin 3757 16,9% 15,3% 29,7% 26,5% 20,0% 52,5% 23,9% 19,5% 19,5% 93,3% 95,5% 91,3% 
Cephalosporins 2nd G 
Cefaclor 4080 10,9% 9,3% 23,8% 22,9% 16,7% 47,5% 19,6% 16,9% 25,3% 95,6% 95,5% 95,7% 
Cefuroxime 4098 10,9% 9,3% 23,8% 23,1% 17,0% 47,5% 21,3% 19,0% 26,3% 95,7% 95,7% 95,7% 
Cefoxitin 3766 4,7% 3,9% 11,7% 11,3% 8,6% 22,2% 10,7% 9,4% 13,3% 93,3% 95,5% 91,3% 
Cephalosporins 3rd G 
Cefotaxime  3766 4,0% 3,4% 8,9% 12,1% 9,6% 22,2% 5,5% 4,3% 8,0% 88,9% 95,5% 82,6% 
Cefixime 3776 4,3% 3,7% 8,5% 11,8% 9,0% 23,2% 6,8% 5,6% 9,2% 91,3% 95,7% 87,0% 
Ceftazidime 2288 2,8% 2,2% 7,5% 4,6% 2,8% 13,0% 7,1% 4,6% 12,8% 19,4% 12,1% 27,6% 
Carbapenems 
Ertapenem  3728 ,5% ,3% 2,0% 2,0% 2,0% 2,0% 3,4% 3,1% 4,0% 60,0% 75,0% 42,9% 
Imipenem 2476 ,6% ,4% 2,3% ,3% ,4%   40,9% 39,1% 45,0% 2,0%   4,2% 
Quinolones 
Ciprofloxacin 3827 18,7% 16,0% 39,6% 25,3% 19,7% 48,5% 30,4% 24,1% 44,0% 29,6% 26,1% 34,3% 
Levofloxacin 435                         
Aminoglycosides 
Gentamicin 3823 7,0% 6,6% 9,7% 15,2% 13,3% 23,2% 14,8% 14,4% 15,8% 8,5% 10,9% 5,6% 
Tobramycin 2271 7,1% 7,0% 8,1% 15,2% 14,1% 20,8% 12,6% 12,6% 12,5% 5,6% 7,4% 3,7% 
Amikacin 93       4,3%   10,0%       12,0% 12,5% 11,1% 
Macrolides Eritromicin 1433 ,9% ,5% 3,9% 3,0% 2,9% 3,3% 4,2% 4,2% 4,2%       
Tetracyclines Tetracycline 432                         
Glycopeptides  Vancomycin  422                         
Lincosamides Clindamycin 350                         
Fosfomycins Fosfomycin 3797 4,7% 3,7% 12,4% 51,5% 52,3% 48,5% 34,9% 30,9% 43,4% 81,0% 87,9% 73,3% 
Nitrofurans Nitrofurantoin 4202 5,0% 4,1% 12,7% 28,9% 28,1% 32,3% 97,9% 97,5% 98,7% 95,7% 95,8% 95,7% 
Sulfamides TMP-SMX 4249 25,1% ,1% 36,4% 24,0% 18,4% 46,5% 39,3% 38,7% 40,8% 95,8% 97,4% 93,9% 
Oxazolidinones Linezolid  422                         
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   Enterococcus sp (%) Staphylococcus spp (%) S. agalactiae (%) Other bacteria (%) 
Class Antimicrobial N = 4270 n = 290 F =222 M = 68 n = 103 F = 79 M = 24 n =50 F = 45 M = 5 n = 279 F = 186 M = 93 
Penicillins 
Ampicillin 3028 38,6% 35,2% 48,1% 28,6% 33,3% 20,0% 0,0%     87,8% 87,9% 87,5% 
AMX-CA 3778 33,3%   100,0% 0,0%     0,0%     60,7% 61,5% 59,1% 
Cephalosporins 1st G Cefalotin 3757 66,7% 50,0% 100,0% 0,0%     0,0%     72,7% 74,6% 69,0% 
Cephalosporins 2nd G 
Cefaclor 4080 94,3% 93,7% 96,2% 82,5% 81,4% 85,7% 6,5% 7,4%   49,2% 44,7% 58,6% 
Cefuroxime 4098 94,4% 93,7% 96,4% 85,7% 83,9% 90,9% 6,3% 7,1%   48,3% 44,1% 56,8% 
Cefoxitin 3766 33,3%   100,0% 0,0%     0,0%     41,7% 43,5% 37,9% 
Cephalosporins 3rd G 
Cefotaxime  3766 33,3%   100,0% 100,0% 100,0%   0,0%     9,0% 7,2% 12,6% 
Cefixime 3776 50,0% 50,0% 50,0% 60,0% 75,0%   0,0%     8,7% 7,3% 11,5% 
Ceftazidime 2288                   12,3% 9,2% 18,6% 
Carbapenems 
Ertapenem  3728 25,0%   100,0% 100,0% 100,0%   0,0%     5,0% 2,9% 9,3% 
Imipenem 2476 34,8% 33,7% 37,5% 83,9% 85,4% 80,0% 0,0%     2,9% ,9% 7,0% 
Quinolones 
Ciprofloxacin 3827 25,0% 33,3%   0,0%     100,0%   100,0% 18,1% 14,1% 26,4% 
Levofloxacin 435 18,0% 16,1% 23,9% 19,8% 10,4% 50,0% 2,1% 2,3%         
Aminoglycosides 
Gentamicin 3823 16,7% 20,0% 0,0%             17,6% 16,6% 19,8% 
Tobramycin 2271                   15,3% 15,3% 15,5% 
Amikacin 93                   6,3%   11,1% 
Macrolides Eritromicin 1433 54,1% 52,3% 59,7% 53,1% 51,4% 58,3% 46,0% 44,4% 60,0% 7,7%   25,0% 
Tetracyclines Tetracycline 432 80,9% 78,7% 88,1% 38,1% 32,9% 54,2% 87,8% 88,9% 75,0% 100,0%   100,0% 
Glycopeptides  Vancomycin  422 25,7% 24,3% 30,3% 20,8% 16,7% 33,3% 9,1% 10,0%   100,0%   100,0% 
Lincosamides Clindamycin 350 92,7% 92,1% 94,3% 57,0% 55,1% 62,5% 51,1% 46,5% 100,0%       
Fosfomycins Fosfomycin 3797 100,0% 100,0% 100,0% 80,0% 75,0% 100,0%       48,9% 45,6% 55,7% 
Nitrofurans Nitrofurantoin 4202 8,7% 8,2% 10,3% 15,4% 10,1% 31,8% 4,2% 4,7%   46,7% 38,5% 63,6% 
Sulfamides TMP-SMX 4249 94,8% 95,5% 92,6% 3,9% 2,5% 8,3% 4,0% 2,2% 20,0% 21,7% 18,4% 28,3% 
Oxazolidinones  Linezolid  422 18,8% 17,2% 23,9% 7,7% 7,1% 9,5% 8,5% 9,3%   100,0%   100,0% 
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FIGURE 5 Variation of antimicrobial resistance pattern of bacteria during the study period (2011-2014). 
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FIGURE 6 Variation of antimicrobial resistance pattern of bacteria over the age groups (children - adolescence - young adults - 
adults - elderly). 
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TABLE 3 Weighted average  of bacterial resistance considering the weight of the total incidence of each uropathogens for women 
and men ; - Not considered, natural resistance; T- Total average resistance; F – Female’s average resistance; M- Male’s average 
resistance; CIPRO – ciprofloxacin; FOS - fosfomycin; NITRO - Nitrofurantoin; AMP – ampicillin ; TMP-SMX – trimethoprim-
sulfamethoxazole; AMX-CA – amoxicillin-clavulanic acid; FOS – fosfomycin; IMP - imipenem; GEN – gentamicin;● Higher than the 
recommendable value (>20%). 
 
  CIPRO FOS NITRO AMP TMP-SMX AMX-CA IMP GEN 
    T F M T F M T F M T F M T F M T F M T F M T F M 
E. coli 64 19 16 40 5 4 12 5 4 13 48 46 67 25 0 36 11 10 20 1 0 2 7 7 10 
Klebsiella spp 12% 25 20 49 52 52 52 29 28 32 99 98 100 24 18 47 18 13 37 0 0 0 15 13 23 
P. mirabilis 6% 30 24 44 35 31 43 - - - 48 47 51 39 15 22 17 15 22 41 39 45 15 14 16 
P. aeruginosa 2% 30 26 34 81 88 73 - - - 96 96 96 96 96 91 93 45 58 2 0 4 9 11 6 
Enterococcus sp 7% 25 33 0 100 100 100 9 9 8 39 35 48 95 96 93 33 13 37 35 34 34 17 20 0 
Staphylococcus spp 1% 0 0 0 80 75 100 15 10 32 29 33 20 4 3 8 0 0 0 84 85 80 0 0 0 
S. agalactiae 0% 100 0 100 0 100 100 4 5 0 0 0 0 4 2 20 0 0 0 0 0 0 0 0 0 
Other bacteria 7% 18 14 26 49 46 56 47 39 64 88 88 88 22 18 28 61 62 59 3 1 7 18 17 20 
Weighted Average   20,6 18 36,7 24,1 23,1 30,3 10,7 9,4 17,4 56,7 55,1 69,8 31,5 12,9 40,9 18,8 15,1 25,2 9,1 6 8 9,8 9,5 11,5 
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4.4. MULTIDRUG RESISTANT BACTERIA IMPLIED IN UTI 
Multidrug resistance to three or more antimicrobial classes was considered and 
defined as MDR. The total percentage of MDR isolates were 1536 (36%), including 
1099 (30.9%) women and 437 (61.6%) men. The percentage of MDR isolates varied 
from 22.4% to 85.2% in all MDR bacteria (Figure 7). The most frequent MDR isolates 
were Enterococcus spp (85.2%), Staphylococcus spp (62.1%), P. mirabilis (58.3%) and P. 
aeruginosa (57.8%). The less frequent MDR isolates were E. coli (22.4%), Klebsiella spp 
(39.8%) and S. agalactiae (44.0%). For the other bacteria group73.1% of isolates were 
MDR (Figure 7). 
The percentage of MDR isolates implicated in UTI were statistically different 
between women and men, considering: E. coli, Klebsiella spp, P. mirabilis and 
Staphylococcus spp (Mann-Whitney U test, p< 0.05). The MDR isolates frequency in 
women was: E. coli (19.7%), Klebsiella sp (32.5%), P. mirabilis (52.4%) and 
Staphylococcus spp (55.7%). The MDR isolates frequency in men was: E. coli (43.8%), 
Klebsiella sp (69.7%), P. mirabilis (77.1%) and Staphylococcus spp (83.3%)(Figure 7). 
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FIGURE 7 Variation of MDR isolates by age groups; d statistical significant 
differences between genders (Mann–Whitney U test, p <0.05); 
The MDR isolates were resistant, on average, to 6 antimicrobials and to 5 
antimicrobial classes of antibiotics. There were also statistical significant differences 
(Mann–Whitney U test, ρ <0.05) between genders. For women, the MDR 
uropathogens were resistant on average to 6 antimicrobials and to 5 antimicrobial 
classes of antibiotics. For men, the MDR uropathogens were resistant on average to 7 
antimicrobials and to 5 antimicrobial classes of antibiotics. 
The prevalence of MDR isolates varied significantly among the age groups 
(Kruskal-Wallis test, p < 0.05). The highest percentages of resistance were observed in 
the elderly (45.2%) and children (31.7%) (Figure 8). The lowest percentages were 
observed in adults (24.9%) and young adults (27.1%) (Figure 8). Significant gender 
differences were also observed in children, adults and elderly (Mann–Whitney U test, 
p <0.05) (Figure 8).  
Universidade de Aveiro Departamento de Biologia 
 2014 
 
98 
 
 
FIGURE 8 Variation of MDR isolates by age groups; d statistical significant 
differences between genders (Mann–Whitney U test, p <0.05); d statistical significant 
differences over the age groups (Kruskal-Wallis test, p < 0.05) 
The percentage of MDR isolates presented a significant decrease throughout 
the study period (10.4%) (Kruskal-Wallis test, p < 0.05). The highest percentage was 
observed in 2011 (40.8%) and the lowest percentage was observed in 2014 (30.4%) 
(Figure 9). During the study period there were also significant gender differences from 
2011 to 2014 (Mann–Whitney U test, ρ <0.05) (Figure 9). 
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FIGURE 9 Variation of MDR isolates over the study period; d statistical significant 
differences between genders (Mann–Whitney U test, p <0.05); d statistical significant 
differences throughout the study period (Kruskal-Wallis test, p < 0.05). 
The highest rates of MDR were observed to ampicillins (83.4%), cefalotin 
(65.5%), tetracycline (77.9%), clindamycin (92.4%) and TMP-SMX (61.4%) for both 
genders. There were statistical significant differences on MDR isolates between 
genders, with exception of amikacin, tetracycline and linezolid (Figure 10).  
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FIGURE 10 Distribution of MDR isolates resistance to the antimicrobials tested - 
total number of bacteria multidrug resistant; Total MDR, N=1536; Female MDR, 
n=1099; Male MDR, n=437; d statistical significant different between genders (Mann–
Whitney U test, p<0.05). 
5. DISCUSSION 
As observed in other studies, E. coli was the most common uropathogen 
implicated in the UTI covering the population of Aveiro North. E. coli bacterium was 
responsible for more than an half of the UTI (64%). Moreover, Klebsiella spp, P. 
mirabilis and Enterococcus spp were also frequently involved in UTI (6 – 12% 
respectively), similar to the observed in other studies performed at community level 
worldwide (Francesco, et al., 2007; Mendo, et al., 2008; Costa, et al., 2009; Narciso, et 
al., 2012; Chatterjee, et al., 2014; Miranda, et al., 2014; Moayednia, et al., 2014). The 
high frequency of these bacteria can be an indicative of self-colonisation by 
gastrointestinal pathogens, since these bacteria are very common in gastrointestinal 
flora and are reported as the main responsible for R-UTI (Al-Badr, et al., 2013). 
Enterobacteriaceae have several factors responsible for their attachment to 
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urothelium, which transform them into the main bacteria responsible for UTI (Dash, et 
al., 2013). Being the three most reported UTI main bacteria (81.2%) in the community 
studies worldwide, would be significant for the empiric treatment success an action 
spectrum for them (Costa, et al., 2009). 
As stated before UTI is more frequent in women than in men (67.8% and 
43.4%, respectively), and the highest difference between women and men patients 
was observed for the P. mirabilis (incidence 10.7%, 2.3 times higher in men) and P. 
aeruginosa (incidence 5.1%, 3.9 times higher in men). E. coli bacterium was the most 
predominant in both genders, however its incidence was significantly higher in women 
(67.8%) than in men (43.4%) (Mann-Whitney U test, p<0.05), which was also observed 
in other similar studies (Linhares, et al., 2013; Chatterjee, et al., 2014). According to 
the literature, P. aeruginosa is more frequent in men due to characteristics inherent to 
the patient, including sex, age, previous use of antimicrobials, previous interventions in 
the urinary tract and patients with neurogenic bladder (Grabe, et al., 2008; Koeijers, et 
al., 2010; Rodrigues, et al., 2011; Linhares, et al., 2013).  
The higher incidence of P. mirabilis in men than in women was consistent with 
published literature (Orrett, et al., 2001). P. mirabilis due to biofilms production 
capacity is a serious medical problem in catheter-associated UTI, which is consistent 
with its higher rates in elderly (Czerwonka, et al., 2014). As reported by Nicolle (2014). 
The elderly age group, especially in men (incidence in men 16% and women 3%), were 
the most frequent catheter-associated UTI patients (Nicolle, 2014). Moreover, 
Pseudomonas and Proteus spp have been found with high frequency in complicated 
UTI, which may justify their high incidence in men, as well as their higher rates in 
children and elderly age groups (Grabe, et al., 2008). 
The average age of men with UTI was significantly higher than women 
(averaged age 68 and 59 years, respectively), which can also explain the aetiological 
differences among genders (Mann–Whitney U test, ρ-value <0.05). The higher 
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incidence of UTI in older men can be due to benign prostate hyperplasia (BPH) and 
neurogenic bladder more common at this age (Koeijers, et al., 2010; Dash, et al., 2013). 
Moreover, the higher incidence of UTI caused by P. aeruginosa bacterium is frequently 
associated with the hospital environment, in men seems to be related to the increased 
hospitalizations due to their higher age (Koeijers, et al., 2010; Nicolle, 2014). Despite 
hospital-acquired urinary infection caused by P. aeruginosa in community is still 
uncommon (1.9% in this study).  However, it should not be ignored, since other 
community-acquired UTI studies have reported its increasing incidence (Koeijers, et al., 
2010; Rodrigues, et al., 2011; Linhares, et al., 2013). 
The distribution into age groups was not random (Chi-square test, p<0.05), the 
incidence of UTI increased with age in both genders. Being the elderly the most 
affected (52%), followed by adults (32%), young adults (12%), children (2%) and 
adolescents (1%). In the literature, it is well documented that the incidence of 
community-acquired UTI increases with age, affecting both genders in the elderly 
population (Cove-Smith, et al., 2007; Linhares, et al., 2013; Chatterjee, et al., 2014). 
The increase in young adult and adult women is well established with the sexual 
activity, the use of contraceptives (spermicides, diaphragm and oral contraceptives), 
the use of antimicrobials and pregnancy (Narciso, et al., 2012). In adult and elder 
women, the increase of UTI has been explained by menopause. After menopause the 
estrogen levels and Lactobacilli number drop and makes post-menopausal women 
susceptible to UTI (Al-Badr, et al., 2013).  Also to elder women the frequent use of 
antimicrobials, the increase of surgical urogenital interventions, urinary incontinence, 
post void residual (PVR), more frequent hospitalization and other pathologies 
associations explain the (Molander, et al., 2000; Rowe, et al., 2013; Rowe, et al., 2014). 
In adult and elder men, the increase of urinary infections has been mainly related to 
benign prostate enlargement causing voiding obstruction which leads to PVR, the use 
of antimicrobials, more frequent hospitalization, urogenital interventions, neurogenic 
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bladder and other pathologies (Narciso, et al., 2012; Dash, et al., 2013; Rowe, et al., 
2014). 
According to the literature (Weir, et al., 2000; Nwokocha, et al., 2014), there is 
an increase of urinary tract infections from children to adolescence, related to the 
onset of sexual activity, which was not observed in this study. The number of urine 
samples from adolescents was much lower compared to those performed by children, 
which may explain the higher frequency of urinary infections in this age group 
compared to the adolescent group. Despite the low incidence, it was observed the 
highest prevalence of gram positive infection in this age group. According to Blumer 
(2009), older children and adolescents also share many features commonly seen in 
adult patients with infections at the same sites, however gram-positive organisms an 
opportunistic agent are the most common cause of bacterial infections in infants, 
children and adolescents, taking advantage of their vulnerability (Blumer, 2009). 
Following the Blumer (2009) study, the most responsible gram negative uropathogen 
in cystitis is the Staphylococci coagulase-negative, which may justify the increase of 
Staphylococcus spp in the adolescent group in this study. 
The incidence of E. coli, responsible for more than an half of the UTI isolates, 
was constant during the study period (variation 60.8-66.0%) but Klebsiella spp has 
shown a 3% decrease and, contrarily, Enterococcus spp registered a 5.3% increase. 
Francesco et al (2007) also registered a slight increase for Enterococcus (0.7%) in his 4 
years study (2002-2005) among the community outpatients. In the study of Kuzdan 
(2014) was also observed a decrease and the increase, respectively, for the species 
Klebsiella pneumonia and Enterococcus faecium (Kuzdan, et al., 2014). For E. coli and 
the remaining bacteria were almost constant throughout the study period.  
The more predominant uropathogen, E. coli, presented the lowest 
antimicrobial average resistance comparing with the remaining bacteria implicated in 
UTI. The resistance to the first line treatment recommended by EAU for uncomplicated 
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UTI was tested for E. coli and revealed low resistance to the three antimicrobials 
recommended (5.0% nitrofurantoin, 18.7% ciprofloxacin and 4.7% fosfomycin). To the 
second line treatment recommended by EUA, E. coli isolates exceeding the 
recommendable value (<20%) for two of the second line treatment, ampicillin and 
TMP-SMX (31.5% and 25.1% respectively), contrary to AMX-CA (11.4%). E. coli high 
resistance to ampicillin and moderate resistance to AMX-CA and SMX have been also 
reported in other studies (Francesco, Ravizzola, Peroni, Negrini, & Manca, 2007).  
Having into account the high incidence of E. coli (63.8%) and the drug 
resistance pattern of the most implicated bacteria in UTI, it was calculated the 
weighted average of resistance. Among the first line choice, that cause little collateral 
damage, only the nitrofurantoin is suitable to be used in the empiric treatment of UTI 
in the community (weighted average resistance of 10.7%, 20.6% and 24.1%, 
respectively, for nitrofurantoin, ciprofloxacin and fosfomycin). The weighted average 
of nitrofurantoin resistance was not determined for P. mirabilis and P. aeruginosa 
because they are naturally resistant to this antimicrobial. Considering the second line 
therapy recommended by EAU, the ciprofloxacin and TMP-SMX are not appropriate to 
treat UTI in the community but the antimicrobial AMX-CA is appropriated to be used in 
UTI empiric treatment (weighted average resistance of 56.7%, 31.5% and 18.8%, 
respectively for ampicillin, TMP-SMX and AMX-CA). 
The antimicrobial resistance also suggest that the choice of empirical 
antimicrobial therapy should have into account the sex of the patient. The 
uropathogens isolated from men presented, on average, resistance to a higher number 
of antibiotics (on average 5) compared to those isolated from women (on average 4). 
This difference was clearly evident in the average resistance of E. coli and Klebsiella 
spp, which presented significant differences for at least 12 of the 18 antimicrobials 
tested (corresponding to 66.7% and 72.2% of the antibiotics, respectively). For the 
remaining bacteria the difference between women and men was also evident, namely 
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for the antibiotics ciprofloxacin, AMX-CA and TMP-SMX. Consequently, the 
antimicrobials AMX-CA and TMP-SMX should be suitable to treat women (resistance 
<20% for the bacteria more implicated in UTI), but should not be used to treat men 
(resistance >20% for all of the bacteria more implicated in UTI, except E. coli). Two 
recent studies also found differences in antimicrobial resistance among genders. In a 
recent Portuguese study the fluoroquinolones were found unsuitable to treat men, 
and also in an Indian study E.coli isolates showed resistance to the majority of 
antibiotics in men (Linhares, et al., 2013; Chatterjee, et al., 2014).  
The resistance of the main bacteria among age groups has presented significant 
differences to the antimicrobial classes tested on young adults and elderly (Kruskal-
Wallis test, p<0.05). For these two age groups, significant statistical differences were 
observed in all antimicrobials classes. As it was observed before in other studies, the 
resistance tendency significantly increases with age (Cove-Smith, et al., 2007; Linhares, 
et al., 2013). The higher rates of resistance in elder patients can be due to the more 
frequent hospitalization of this age group, as a result of the increase of average life 
expectancy, weak immune system and recurring infections. It is recognized that 
hospitalizations increase the transmission of bacterial strains between hospital and 
community (Ott, et al., 2013). 
In general, the resistance by the main bacteria implicated in UTI to penicillins, 
2nd and 3rd generation cephalosporins, lincosamides, fosfomycins, carbapenems and 
macrolides decreased during the study period. However, for glycopeptides, 
quinolones, aminoglycosides, nitrofurans, sulfamides and oxazolidinones the 
resistance was almost constant throughout the study period to the main 
uropathogens. Nevertheless, S. agalactiae presented a resistance increase over the 
study period to the tetracyclines, glycopeptides, lincosamides and macrolides. P. 
aeruginosa presented a different pattern of resistance relatively to the antimicrobials 
1st to 3rd generation cephalosporins and sulfamides, comparing to the other gram-
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negative (E .coli, P. mirabilis, Klebsiella spp). E coli resistance was constant throughout 
the study period to all antimicrobials tested. According to Linhares et al (2013), the 
pattern of resistance to the main bacteria also showed significant changes during a ten 
years period, but E. coli did not show significant changes in the resistance to the tested 
antimicrobials. Similarly, P. aeruginosa had also a different behaviour compared to the 
gram negative bacteria (E.coli, P. mirabilis, P. vulgaris, Klebsiella spp, Enterobacter spp 
and Providencia spp) throughout the study period, specially observed in the classes of 
cephalosporins and quinolones (Linhares et al., 2013). 
The resistance to first and second line therapy it is probably the reflection of 
their misuse and/or overuse (Bartoloni, et al., 2004). Although most organisms remain 
susceptible to nitrofurantoin, Pallett (2010) defends that this agent is licensed for 
lower UTI only and it has shown that resistance may develop during treatment (Pallett, 
et al., 2010). The oral options available for the treatment of UTI with simultaneous 
resistance to trimethoprim and quinolones are small. As a suitable alternative to first 
and second line recommended therapy, this study recommends imipenem and 
gentamicin to empiric treatment, due to the low bacterial resistance to these drugs in 
both genders, and also considering the low percentage of bacterial resistance to both 
antimicrobials in the MDR isolates. However, gentamicin is contraindicated in patients 
with significant renal impairment, which is more common in the elderly. It is also 
required the regular monitoring of pre-dose serum concentrations to assess further 
dosing (Pallett, et al., 2010). Imipenem can be used in empiric treatment of 
complicated UTI in view its broad spectrum of action and wide diffusion in the body 
(intravenous) (Pallett, et al., 2010). These drugs involve the inconvenience of 
parenteral administration and it can be more expensive than those indicated for UTI. 
The multidrug resistant isolates were observed among the most prevalent 
bacteria involved in the community-acquired UTI, being a 36% of these bacteria 
resistant to three or more antimicrobials of distinct classes. However, the most 
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implicated bacteria in UTI, E. coli, responsible for more than half of the UTI of the 
studied patients, presented the lowest MDR bacterial percentage (22.4%). The second 
bacteria more implicated in the community-acquired UTI, Klebsiella spp, presented 
also a low percentage of MDR isolates (39.8%). Considering the main bacteria more 
implicated in UTI, the percentage of MDR bacteria in this study was higher than that 
found in the Antimicrobial Resistance Epidemiological Survey on Cystitis (ARESC) study, 
which 10.3% of bacteria isolated at community level in nine European countries and in 
Brazil were MDR (Heijer, et al., 2010). However, it was very similar to that obtained in 
a similar study performed at the community level in which 36.7% of isolates 
responsible for UTI were MDR (Heijer, et al., 2010; Sheerin, 2011). Keeping in view the 
more implicated bacterium in UTI, E. coli, higher percentages of MDR isolates have 
been detected in other studies (35.9-72.7%) done at the community level (Sulikowska, 
et al.,  2001; Narciso, et al., 2011; Sheerin, 2011). In this study, the most predominant 
gram negative bacteria and S. agalactiae presented lower percentages of MDR isolates 
(between 22.4% and 44%). The highest percentages were observed among the other 
gram positive bacteria (Enterococcus spp, P. aeruginosa and Staphylococcus spp) and 
the other bacteria group (between 62.1% and 85.2%). 
The MDR bacteria isolated from men were, on average, resistant to a higher 
number of antimicrobial classes than those isolated from women and the higher 
percentage of MDR was also observed in men (61.6%). Most of the UTI in men are 
complicated (associated with structural or functional abnormality in urinary tract), 
requiring prolonged antimicrobial therapy and antibiotics able to reach high 
therapeutic concentrations in the prostatic tissues (Hooton, 2000; Kuroda, et al., 2005; 
Magiorakos, et al., 2011). For these reasons, men are more likely to develop resistance 
to other antibiotics, usually used with success in the treatment of UTI in women 
(Sheerin, 2011). Corroborating this hypothesis, Baral and colleagues showed that the 
percentage of MDR was higher when bacteria were isolated from men (58.7%) (Baral, 
et al., 2012). 
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Nearly 45.2% of the bacteria isolated from elderly patients were MDR. This may 
be explained by the increase of number and duration of hospital admissions with the 
increasing age of the patient. During hospitalization some invasive procedures as 
catheterization and other interventions may be associated with the transmission of 
resistant hospital bacteria to the elderly patients. The immune system fragility of the 
elderly patients may also explain the increase of urinary infection incidence and also of 
UTI caused by MDR bacteria (Kisich, et al., 2008). In this study, patients with 
community and hospital-acquired UTI were included which can validate the MDR high 
percentages in isolates from men. 
The incidence of MDR bacteria decreased about 10.4% throughout the study 
period which may be related with the decrease of the antimicrobial resistance of some 
MDR bacteria during the study period, such as, Enterococcus spp, Staphylococcus spp 
and other bacteria group that showed high averaged percentage of MDR, 85.2% and 
62.1%, respectively. 
6. CONCLUSIONS 
The most prevalent bacteria responsible for UTI were gram negative 
Enterobacteriaceae (E.coli, Klebsiella spp and P. mirabilis) and Enterococcus spp. Being 
E.coli, Klebsiella spp and P. mirabilis the three most common bacteria responsible for 
UTI in the community studies worldwide, would be significant for the empiric 
treatment success an action spectrum for them. 
The results of this study emphasized the relevance to consider sex and age as 
differentiator factors in the choice of UTI empirical treatment, due to differences in 
aetiology and in antimicrobial resistance. The episodes of UTI are undoubtedly higher 
in women and in the elderly group, increasing the differences in the incidence 
between women and men with age. In general, men were more resistant to 
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antimicrobials (on average 5) and to antimicrobial classes resistance (on average 4) 
than women (2 and 2, respectively). 
The results obtained in this study suggest that from first line treatment 
recommended by the EAU to empirical treatment of uncomplicated UTI only 
nitrofurantoin is appropriated for both sexes and ciprofloxacin may be only considered 
to treat women. In the second line antibiotic, ampicillin is not an appropriate drug to 
empirical treatment of uncomplicated UTI, though the antimicrobials AMX-CA and 
TMP-SMX should not be used to empirical treatment of men, due to the local high 
incidence of resistance (> 20%). As alternative to first and second line recommended 
treatment, imipenem and gentamicin should be used due to their low weighted 
average percentage of resistance. 
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